

Cite this: *RSC Adv.*, 2013, **3**, 22706

Structural analysis of glycoprotein sialylation – part II: LC-MS based detection

Giuseppe Palmisano,^{*ab} Martin R. Larsen,^a Nicolle H. Packer^c and Morten Thaysen-Andersen^c

Structural characterisation of sialylated glycoproteins in time and space is a requirement for further understanding of their involvement in biology. In this second of two related reviews, our focus is on the liquid chromatography (LC) and mass spectrometry (MS) based techniques, which have become the golden analytical tools in recent decades for the analysis of *N*- and *O*-linked glycoprotein sialylation. Analytical strategies for the analysis of *N*- and *O*-linked sialoglycoproteins and pre-LC-MS aspects including enrichment, derivatisation and metabolic labelling techniques were covered in the first review. Acknowledging that glycoprotein sialylation can be studied on multiple analyte levels, LC-MS detection of sialoglycans, sialoglycopeptides and intact sialoglycoproteins are separately discussed. All levels have benefitted from continuous improvements of LC-MS technologies, which have gradually pushed the boundaries for separation and detection capabilities to finally allow characterisation of sialoglycoproteins more directly from biological samples. Although still not achieved from a single analysis, LC-MS facilitates the characterisation of many aspects of the sialoglycoprotein structure including the identification and quantitation of the protein carrier, the underlying glycan structure and the sialyl linkage as well as the sialic acid speciation and its further modifications. It is evident from the body of literature that the analytical glycoscientist now has a much improved, though not yet fully mature, toolbox for the analysis of glycoprotein sialylation. This capacity enables structural based investigations of the functional relevance of sialoglycoproteins. Understanding the chemistry and biology of the conjugated sialic acids is essential in order to interpret the complex protein glycosylation code.

Received 14th June 2013

Accepted 13th September 2013

DOI: 10.1039/c3ra42969e

www.rsc.org/advances

1. Introduction

Mass spectrometry (MS) based molecular mass determination in structural and dynamical biology is sensitive, accurate, fast and robust, and has the ability to be coupled to a range of separation techniques.¹ These properties have made MS the analytical detection tool of choice to structurally analyse the multitude of biomolecules encountered in nature including sialylated *N*- and *O*-linked glycoproteins,² which are the focus of these two related reviews. The general structures and diverse biological functions of the most common mammalian sialic acids (*i.e.* *N*-acetylneurameric acid (Neu5Ac) and *N*-glycolylneurameric acid (Neu5Gc)) were introduced in *Part I* of the two reviews.³ The importance of characterising the structures of

sialic acids and their conjugates in order to increase our understanding of their chemistry and biology and to take further steps towards being able to interpret the complex protein glycosylation code were stressed.

Modern day mass spectrometers are capable of handling the large mass range spanning the spectrum from the relative low molecular mass of released sialoglycans (typically 0.5–3 kDa) over proteolytically generated sialoglycopeptides (typically 2–10 kDa) to intact sialoglycoproteins (typically >10 kDa) with high resolution, sensitivity and mass accuracy, in particular in the lower *m/z* end of the spectrum.⁴ In addition, free sialic acids (*e.g.* Neu5Ac or Neu5Gc) and their modified counterparts,⁵ sialic acid sugar nucleotides (*e.g.* CMP-Neu5Ac or CMP-Neu5Gc)⁶ and free (non-protein linked) sialoglycans⁷ can also be detected by MS, but will not be covered here as we will focus strictly on the analysis of the sialic acids carried by *N*- and *O*-linked glycoproteins. Although the linear repeats of sialic acid residues, termed oligo- and poly-sialic acids, can be carried by *N*-glycoproteins, this review will only briefly touch on these structures since very limited literature is available regarding their analysis.^{8,9}

^aDepartment of Biochemistry and Molecular Biology, University of Southern Denmark, Campusvej 55, DK-5230 Odense M, Denmark. E-mail: giuseppe@bmb.sdu.dk; Fax: +45 6550 2467; Tel: +45 6550 2342

^bInstitute of Biomedical Sciences, Department of Parasitology – USP, São Paulo, Brazil

^cDepartment of Chemistry and Biomolecular Sciences, Macquarie University, Sydney, Australia

Depending on the purity of the sialylated glycoconjugate(s) of interest it is often desirable to separate the analytes prior to MS detection to avoid ion suppression and to maximise the number of molecular precursors that can be fragmented by tandem MS in order to facilitate further structural characterisation and confirmation. This is particularly useful for sialylated glycoconjugates where multiple isobaric molecules may be hidden under an identical molecular mass. Although other techniques are showing promising potential for the separation of sialylated compounds including capillary electrophoresis (CE) and ion mobility spectrometry (IMS) as discussed briefly in this review, separation is most commonly performed using a variety of liquid chromatography (LC) techniques. On-line LC separation, where the sialylated analytes are eluted directly from the LC column into the hyphenated mass spectrometer, is preferred when detection is performed using electrospray ionisation (ESI) MS. In contrast, different types of off-line LC

separation techniques are usually favoured, or even avoided, when using matrix assisted laser desorption ionisation (MALDI) MS detection. Although MALDI MS has certain advantages including higher speed of data acquisition and ease of data interpretation, ESI MS is the most used detection technique in glycoscience due to the potential for LC hyphenation.^{10,11} The LC method should be carefully chosen by considering the physicochemical or structural properties of the sialylated analytes of interest. The negative charge of sialoglycoconjugates is naturally a useful molecular feature that can be used to separate asialo and sialo-compounds as well as differently sialylated species. Loss of sialic acids from the sialylated analyte during LC is usually not a problem even when the chromatography is carried out in very acidic solvents, however, it is recommended that excessive column heating is avoided and that acidic solvents are evaporated if the sialylated analytes are stored for an extended period post separation.¹²⁻¹⁴ The conditions applied



Dr Giuseppe Palmisano is currently appointed professor at the Department of Parasitology, University of São Paulo, Brazil. He obtained his Ph.D. degree in mitochondrial physiopathology in 2008 from University of Bari under the supervision of Prof. Sergio Papa and then completed a postdoctoral fellowship at the University of Southern Denmark with Prof. Martin Larsen, developing methods for PTMs analysis in different biological samples.

He obtained the Young Investigator Award at HUPO 2011 in Geneva. His current area of research is proteomics applied to cancer metastasis and parasite infections with a particular attention on regulatory mechanisms of PTMs-mediated cellular signals.



Prof. Martin R. Larsen is currently professor in clinical proteomics at the University of Southern Denmark and head of the Centre for Clinical Proteomics in Odense, Denmark. He obtained his Ph.D. degree in 2000 from University of Southern Denmark and then completed a postdoctoral fellowship at the APAF at Macquarie University in Sydney, Australia. In 2009 he obtained the Lundbeck Junior Group Leader Fellowship. His area of research is proteomics applied to biomedical and biological systems. He has developed several methods for the mass spectrometric characterization of phosphorylated proteins and glycosylated proteins, which are used by researchers worldwide.



Prof. Nicki Packer was part of the team that established the Australian Proteome Analysis Facility (APAF) and co-founded Proteome Systems Limited, an Australian biotechnology company in which her group developed a platform of glycoanalytical technology and informatics tools. She is now Professor of Glycoproteomics, Director of the MQ Biomolecular Frontiers Research Centre and Consultant to APAF at Macquarie University, Sydney, Australia. She has gained an international and national profile by linking glycomics (the glycosylation profile of the expressed genome) with the proteomics and genomics approaches to biological functional research.



Dr Morten Thaysen-Andersen currently holds a three-year ARC Super Science Research Fellowship position at Macquarie University, Sydney, Australia. He obtained his Ph.D. degree in glycoproteomics in 2009 from University of Southern Denmark, and then completed a two-year post doctoral fellowship in glycobiology at Macquarie University with Prof. Nicolle H. Packer funded by the Danish Research Agency. His current research is conducted in the area of structural glycobiology with a strong focus on understanding how human N- and O-linked protein glycosylation affects glycoprotein function in a variety of biological systems, including hormone binding/delivery and pathogenic-host interactions in the context of cystic fibrosis.



during sample preparation are also very important to consider in order to keep the sialoglycoconjugates intact and avoid undesired derivatisation.³

Following on from the first of these two related reviews, which described the analytical strategies and pre-LC-MS tools for the analysis of glycoprotein sialylation,³ this second part summarises the present LC-MS based techniques in the context of glycoprotein sialylation analysis. Here released sialoglycans and sialoglycopeptides are covered separately due to the dedicated workflows and considerations required for their respective analyses (see overview of topics covered by parts I and II in Fig. 2 (ref. 3)). Relatively little analytical work has been presented for sialoglycoproteins; techniques dealing with these larger analytes are consequently discussed under the sialoglycopeptide section. The techniques and tools for general analysis of protein glycosylation have been reviewed previously.^{2,15–18} Here we will focus strictly on the sialylated component of the glycome/glycoproteome. It is stressed that the majority of the presented LC-MS based techniques are not only capable of analysing sialylated glycoproteins, but also their neutral counterparts; however, the techniques are irrespectively discussed

with a sialic acid centric focus in this review. The bioinformatics tools for the management and interpretation of LC-MS and tandem MS data and the use of glycosylation databases/repositories will not be covered here. Instead the reader is referred to other recent resources for detailed reviews.^{15,19–21}

2. LC-MS analysis of sialoglycans

2.1 LC separation of sialoglycans

The hydrophilicity and small molecular mass/size are physico-chemical features that allow relatively easy isolation of *N*- or *O*-linked glycans following release from their protein carriers in biological samples.³ In addition, the mammalian glycome has a somewhat limited number of analytes due to the enzymatic restrictions in the biosynthetic glycosylation machinery.²² Together, this means that the glycan mixtures released from proteins usually have much lower analyte complexities compared to equivalent peptide mixtures encountered in proteomics type experiments. The complexity is naturally reduced even further when the focus is restricted to encompass only the sialylated component of the *N*- and *O*-linked glycome. The main




Fig. 1 PGC LC-MS separation and detection of sialylated *N*-linked glycans released from bovine fetuin. The sialoglycans were reduced prior to analysis, but otherwise undervatived. Detection of the separated sialoglycans was performed using negative ion ESI IT MS. Structures have been assigned in the relevant extracted ion chromatograms for five *m/z* ratios corresponding to the major monosaccharide compositions for the reported *N*-linked sialoglycans from bovine fetuin.^{250,251} The high separation power of PGC for sialylated *N*-glycan isomers is showcased by its ability to separate sialoglycans with variations in their numbers of antennas/sialic acid residues and their linkages/branch points. Increasing number of sialic acid residues and antennas generate a stronger retention on PGC. In addition, glycans containing α 2,6-linked sialic acid residues elute significantly before the α 2,3-linked counterparts.

Table 1 Overview of the isomer separation and retention behaviour of *N*- and *O*-linked sialoglycans and sialoglycopeptides for the most common LC methods in glycomics/glycoproteomics (see main text for more information of the individual LC methods)

	Chromatography	Separation of Neu5Ac composition isomers	Separation of sialo-topology isomers	Separation of sialo-linkage isomers
Sialoglycans	PGC	Yes (higher # Neu5Ac → more retention)	Yes (structure specific retention) ^b	Yes (sialyl α 2,6 < sialyl α 2,3)
	HILIC	Yes (higher # Neu5Ac → more retention)	Yes (Neu5Ac on 3' arm < Neu5Ac on 6' arm)	Yes (sialyl α 2,3 < sialyl α 2,6)
	RPC ^a	Yes (higher # Neu5Ac → more retention)	Weak separation ^c	Weak separation ^c
Sialo-glycopeptides	RPC	Yes (higher # Neu5Ac → more retention) ^d	Weak (if any) separation	Weak (if any) separation
	HILIC ^e	Yes (higher # Neu5Ac → less retention) ^e	Weak (if any) separation	Weak (if any) separation

^a Permethylated or labelled glycans. ^b No general retention rule seem to apply; occasionally Neu5Ac on 3' arm < Neu5Ac on 6' arm and occasionally Neu5Ac on 3' arm < Neu5Ac on 6' arm.³⁸ ^c Weak separation of topology and/or linkage isomers was obtained using IP RPC of 2-AB labelled *N*-glycans.^{52,58} ^d When IP conditions are used sialylated *N*-linked glycans containing a higher number of Neu5Ac residues are less retained on RPC. ^e This retention behaviour applies for ZIC HILIC separated sialoglycopeptides; other HILIC phases may retain sialoglycopeptides differently.

challenge in this context is, as such, usually not the number of sialoglycans in the mixture, but the close molecular relatedness that complicates their separation. For example, isobaric sialoglycans varying only in a sialyl linkage or in the location of a terminal sialic acid residue commonly occurs in biological samples. This emphasises the need for utilising LC techniques with high separation power for analytes with such small molecular discrepancies.

2.1.1 PGC. The general utility of porous graphitised carbon chromatography (PGC) in the analysis of glycans has been recently reviewed.²³ PGC has been used for several decades to separate glycans with high resolution of structural isomers.^{24,25} Nowadays, PGC is typically coupled directly to the mass spectrometers for on-line detection. The chromatography, which is typically performed with HyperCarbTM stationary phase at micro- or nano-scale flow rates to maximise the detection sensitivity, can be carried out in conventional capillary/nano-LC columns²⁶ or in microfluidic chip based formats²⁷ that have become commercially available (e.g. mAB-Glyco Chip, Agilent). Although the exact retention mechanism(s) of PGC remains somewhat controversial, it is broadly accepted that the retention properties are of mixed character, involving hydrophobic, polar and ionic interactions with the hexagonal graphite structures of the stationary phase.^{25,28,29} The polar and ionic nature of sialic acid residues allows sialoglycans to be well retained on PGC. Slightly alkaline solvents (e.g. 10 mM ammonium bicarbonate in water and acetonitrile, pH 7.8) are typically used for the separation of neutral and sialylated *N*- and *O*-linked glycans using PGC.^{30,31} These conditions are readily compatible with the high PGC column stability (pH 0–14), the subsequent MS ionisation, and the stability of sialoglycans. For the latter, it should be considered that the α -glycosidic linkage of sialic acid residues can hydrolyse under more acidic conditions.¹² Another benefit is that the slightly alkaline mobile phases generate sialoglycans that are more efficiently ionised in negative ion MS as discussed later. The separation of the sialoglycans on the PGC column is enabled by a shallow gradient of increasing concentration of acetonitrile. Some researchers use more alkaline

conditions e.g. 0.04% ammonium hydroxide in water and acetonitrile (pH 11). This enhance the detection of *N*- and *O*-linked sialoglycans in nano-flow PGC compared to the detection using capillary PGC-MS at pH 8.^{32,33} In contrast, an acidic solvent system consisting of 65 mM formic acid in water or acetonitrile buffered to pH 3.0 showed other benefits of strong retention of sialylated glycans and an overall increase in the peak capacity.³⁴ The influence of electrosorption, solvent, temperature and ion polarity on the performance of PGC based separation of sialylated glycans has been systematically investigated.³⁴ Here it was concluded that ionic strength and pH of the mobile phase significantly influence the elution profile and the peak shape of the sialoglycans. In addition, it was stressed that electrical grounding of the PGC column was needed in the LC-MS setup to eliminate total retention of highly sialylated glycans on the PGC column due to electrical polarisation of the stationary phase even when non-conductive tubings from the column to the source were used. Regeneration may also be required to extend the life time and the performance of the PGC column.^{34,35} PGC is, as such, a more challenging separation technique to utilise compared to RPC. Weak heating of the PGC column to 45–55 °C can be performed to lower the back pressure and increase the retention and peak capacity, but higher temperatures should be avoided due to the heat sensitive sialyl linkages.^{14,34,36,37}

Native (underivatised) sialoglycans are commonly separated using PGC, which avoids qualitative and quantitative distortions of the profile due to incomplete or biased chemical derivatisation or degradation. However, simple NaBH₄ based reduction of the released sialoglycans to the alditol form is needed to yield a single peak for each eluting compound due to the α - and β -anomer formation of non-reduced glycans that separate well on PGC.³⁰ PGC is arguably the LC method with the highest separation power of sialoglycans since its means of separation to resolve for example isobaric isomers is more orthogonal to the subsequent mass separation in the mass spectrometer than other LC separation techniques.¹⁷ This is evidenced by the separation by PGC of closely related structural



variations of sialoglycans (see Fig. 1 for an example of a PGC separation of *N*-linked sialoglycans and Table 1 for an overview of LC based separation of sialoglycans and sialoglycopeptides). As such, PGC has the potential to separate: (i) sialoglycans with different monosaccharide compositions *e.g.* different number of Neu5Ac residues and/or Neu5Ac/Neu5Gc variants, (ii) sialoglycans with the same monosaccharide composition, but with different topologies *e.g.* Neu5Ac residues on the 3' or 6' arm of *N*-linked sialoglycans, and (iii) sialoglycans with the same monosaccharide composition and topology, but with different sialyl linkage types *e.g.* α 2,3- or α 2,6-linked Neu5Ac residues. Sialoglycans having a higher number of sialic acid residues and a higher number of antennas have a greater retention on PGC than less sialylated and less branched sialoglycans. In addition, α 2,6-sialylated glycans have been shown to elute well before their α 2,3-sialylated counterparts when applying a normal gradient of increasing acetonitrile concentration. As such, the retention order of the sialoglycans can assist in their structural characterisation.³⁸ This is particularly useful for linkage-type isomers where molecular mass and tandem MS fragmentation often fail to confidently differentiate isobaric sialoglycans *e.g.* those isomers that differ only in the sialyl linkage type. The separation power of PGC-MS was recently demonstrated in a study where nearly 300 mouse serum *N*-glycan compounds from over 100 distinct monosaccharide compositions were separated.³⁹ Together with MS/MS analysis this revealed a number of novel sialylated *N*-glycan structures as well as other modifications such as dehydration, *O*-acetylation and lactylation.

2.1.2 HILIC. Hydrophilic interaction liquid chromatography (HILIC), also known as aqueous normal phase chromatography (NPC), is another powerful tool to separate sialylated glycans. The use of HILIC in structural glycomics and glycoproteomics has recently been reviewed.^{40–42} Many different stationary HILIC phases of polarised uncharged or charged nature are available⁴³ and the solvent systems, which are usually made up of acetonitrile, water and a pH and salt modifier/component, are mostly compatible with the MS analysis of sialoglycans. The retention mechanism of pure HILIC is described as hydrophilic partitioning of the analyte to the aqueous layer surrounding the hydrophilic stationary phases.⁴⁴ The retention time of glycans on neutral polar stationary phases including polyhydroxyethyl (PolyLC) and amide based phases (Tosoh) is largely defined by the number of hydroxyl groups of the glycans and, hence, their number of monosaccharides.⁴³ On charged stationary phases such as the zwitter-ionic (ZIC) HILIC (Sequant Merck), which represents one of the most used sorbents for glycomics and glycoproteomics, additional contributions to the retention mechanisms including electrostatic interactions/repulsions can modulate the actual retention behaviour of glycans containing sialic acid residues and other charged moieties. These secondary effects can be altered by the organic modifier as well as by the salt and pH of the mobile phase.⁴⁵

In one of the first glycomics applications using ZIC HILIC, neutral *N*-glycans labelled at their reducing end with 2-amino-pyridine (PA) were well separated.⁴⁶ Later, ZIC HILIC was demonstrated to be capable of separating 2-aminobenzoic acid (2-AA) derivatised *N*-linked sialoglycans according to their

number of sialic acid residues.⁴⁷ In addition, the separation of PA derivatised sialylated *N*-glycans including α 2,3-/ α 2,6-Neu5Ac and β 1,3-/ β 1,4-Gal linkage isomers were convincingly achieved using a ZIC HILIC phase.⁴⁸ High separation capacity of ZIC HILIC was also illustrated in another study where a two-dimensional on-line LC approach consisting of HILIC and anion-exchange chromatography was sufficient to separate PA-labelled sialylated *N*-glycan topology isomers (*i.e.* Neu5Ac on 3' or 6' arm).⁴⁹ Here, ZIC HILIC was shown to have a higher separation power for sialoglycan isomers than a neutral amide based (polar) stationary phase. α 2,3-sialylated glycans have been shown to elute slightly before their α 2,6-sialylated counterparts,⁵⁰ but with less separation than on PGC (see Table 1 for overview of sialoglycan retention behavior for a variety of LC methods). New sub-2 μ m particles of another neutral HILIC sorbent have improved the peak capacity when operated with ultra-high performance LC (UPLC).⁵¹ In a comparative study, HILIC was evaluated to have a higher separation power of labelled sialylated and neutral *N*-glycans than PGC and reversed phase chromatography (RPC).⁵² Amide HILIC columns are now available in chip-based formats for sensitive and easy analysis of sialoglycans.^{53,54}

2.1.3 RPC. Reversed phase chromatography (RPC), which is the most common separation mode in modern LC-MS, can retain and separate sialylated glycans, but only after increasing the hydrophobicity of the sialoglycans by permethylation/periacylation or labelling of their reducing end with a hydrophobic tag.^{2,3} PA-labelled⁵⁵ or permethylated and 2-aminobenzamide (2-AB) derivatised⁵⁶ sialoglycans have been shown to be separated on RPC according to their number of Neu5Ac residues. Derivatisation techniques of sialoglycans are generally covered in the first of these two reviews (*Part I* – paragraph 3.1.2).³ Higher numbers of sialic acid residues and antennas increase the relative retention time of such derivatised sialoglycans on RPC, Table 1. Although RPC lacks the separation power observed for PGC and HILIC for most fine isomeric glycan features, the α and β anomers of glycans with a free reducing end can be resolved,⁵⁶ stressing the need for performing reduction or reductive amination of sialoglycans prior to RPC analysis. One study demonstrated that labelled IgG *N*-linked sialoglycans can be well separated from their asialylated counterparts by their early elution from the RPC column.⁵⁷ Recently, it has been shown that the addition of an ion pairing (IP) reagent such as diethylamine or triethylammonium to the mobile phase increases the resolution of RPC and enables isomeric separation of derivatised sialoglycans.^{52,58} Some of the common sialic acid monosaccharides *i.e.* Neu5Ac, Neu5Gc and 3-deoxy-manno-octuloseonic acid (Kdo) can also be separated efficiently on RPC in their free form after hydrolysis and derivatisation with 1,2-diamino-4,5-methylene dioxybenzene.⁵⁹

2.1.4 Other separation techniques. As reviewed recently,⁶⁰ high pH anion exchange chromatography (HPAEC), which is mostly known for its ability to detect and quantify monosaccharides including free Neu5Ac and Neu5Gc,⁶¹ is also capable of separating sialylated *N*-glycans according of their number of sialic acid residues and even their linkage type.⁶² In addition, polysialic acid containing *N*-glycans released from



bovine neural cell adhesion molecule (NCAM) or free polysialic acids were well-separated according to their number of α 2,8- and α 2,9-linked sialic acid residues using HPAEC.⁶³ Although HPAEC has been directly coupled to MS,⁶⁴ it is usually undertaken off-line due to the high salt of the mobile phase. The technique is rather insensitive compared to on-line MS detection as a consequence of the pulsed amperometric detection. Off-line anion exchange chromatography (AEC) was also shown to separate *N*-linked sialoglycans derived from erythropoietin (EPO) according to their number of sialic acid residues.⁶⁵ In addition, PA-labelled sialylated *N*-glycans were accurately mapped in three LC dimensions using AEC, hydrophobic and hydrophilic interaction modes.⁶⁶

Although not LC based, other techniques can separate sialoglycans. Ion mobility spectrometry (IMS), which separates analytes based on molecular cross-section in the gas phase, is a promising separation technique for analytical glycoscience. Similarly to PGC, the separation using IMS is more orthogonal to the downstream mass based separation in the mass spectrometer compared to, for example HILIC, due to its structure based distinguishing properties. IMS can be utilised alone with MS based detection or in conjunction with other separation techniques.^{67–69} A few examples demonstrate that IMS is capable of separating sialylated *N*-glycan isomers including ones with different numbers of sialic acid residues and isobaric 3' and 6' arm sialic acid topological isomers.^{70,71} In addition, capillary electrophoresis (CE), also known as capillary zone electrophoresis, is a powerful separation technique that was shown to separate underivatised *N*-linked sialoglycans differing in the number of sialic acid residues.⁷² In other studies, CE combined with laser-induced fluorescence, or with MSⁿ fragmentation in negative ion MS of *N*-linked glycans labelled with 8-aminopyrene-1,3,6-trisulfonic acid trisodium (APTS) or 8-aminonaphthalene-1,3,6-trisulfonic acid (ANTS) was used to separate and identify sialylated and non-sialylated *N*-glycans.^{37,73} In addition, APTS labelled *O*-acetylated sialylated *N*-glycan isomers were recently separated using CE-MS proving that the method has high separation power for modified sialoglycans and is sufficiently gentle to retain the labile acetyl moieties during analysis.⁷⁴ Finally, fluorophore-assisted carbohydrate electrophoresis is a less used separation technique that nonetheless is capable of separating ANTS labelled *N*-linked sialoglycans with different number and types of sialic acid residues, whilst it cannot resolve topology isomers of isobaric sialoglycans.⁷⁵

2.2 MS detection of sialoglycans

The general use of MS techniques in glycomics has been covered elsewhere.^{18,76,77} Some MS aspects in sialic acid-focused glycomics were recently introduced⁷⁸ and the reader is referred to this review as an alternative literature resource.

The relatively low molecular mass of sialoglycans is well-suited for MS, where the technique generally shows its highest sensitivity (low 10^{-12} to 10^{-15} mol), resolution ($>10\,000$), dynamic range (several orders of magnitude) and mass accuracy (low or sub ppm). However, these optimal performance

characteristics are heavily instrument dependent and are rarely achieved in a single experiment using a single instrument. The high speed of modern mass spectrometers (*i.e.* 5–50 tandem mass spectra per second) should be sufficient to cover multiple co-eluting compounds from even the most complex mixtures of sialoglycans; however, sialoglycan mixtures showing a large dynamic range are still challenging to profile and may leave some low-abundant sialylated glycans undetected in the mass spectrometer.

2.2.1 MALDI MS. Many general aspects of matrix assisted laser desorption ionisation (MALDI) MS for glycan analysis have explicitly been reviewed.^{14,79–83} Although many researchers prefer electrospray ionisation (ESI) MS for sialoglycomics, MALDI MS has certain advantages such as higher sensitivity, speed of analysis and ease of operation and data interpretation. Recently, it was stated that “MALDI spectra of *N*-glycans are more useful than ESI spectra because they give a better representation of the glycan profile as the result of predominantly one singly charged ion from each glycan in the mixture and a general absence of fragment ions”.⁸⁴ Because of the speed, MALDI MS is ideal for structural characterisation of sialoglycans using sequential exo/endo-glycosidase treatment, which can be performed directly on the MALDI target plate,⁸⁵ and reanalysis of the sample to observe mass shifts as a result of release of specific monosaccharides.⁸⁶ This was for example performed for polysialic acid containing sialylated *N*-glycans derived from calf NCAM following removal of the α 2,8-linked sialic acids.⁶³

2.2.1.a Ionisation. Where neutral glycans afford strong signals as $[M + Na]^+$ ions in positive ion MALDI MS, signals for sialoglycans are usually stronger as $[M - H]^-$ in negative ion mode. Sialoglycoconjugates are inherently challenging to analyse in MALDI MS due to the instability of the α -glycosidic sialyl bond yielding potential in-source and post-source fragmentation by the loss of CO_2 or the entire sialic acid.⁸⁷ In addition, significant cation adduction to the negatively charged carboxyl group occurs in positive ion MALDI MS. Taken together, this means that intact sialoglycans are often observed at low signal strength in MALDI MS and that special considerations are required for their analysis. The matrix choice, sample preparation and MS settings are consequently of prime importance to facilitate a successful structural characterisation of sialoglycans using MALDI MS.

2.2.1.b Matrix choice. The common MALDI matrices for protein chemistry and proteomics including 2,5-dihydroxybenzoic acid (DHB), α -cyano-4-hydroxycinnamic acid (CHCA) and 2-(4'-hydroxyphenylazo)benzoic acid have repeatedly been shown to be unsuitable for the MALDI MS based analysis of sialoglycans due to significant losses of sialic acids during ionisation under normal acquisition settings. Instead, cooler matrices with lower energy transfer to the analyte are typically favoured such as 6-aza-2-thiothymine (ATT),⁸⁸ 2,6-dihydroxyacetophenone⁸⁹ and 2,4,6-trihydroxyacetophenone (THAP) in the presence of low concentrations of ammonium citrate.⁹⁰ In particular THAP yielded no evident in-source fragmentation of sialoglycans in negative ion MALDI MS with linear mode acquisition while retaining the high sensitivity of the detection






Fig. 2 Site-specific relative quantitation of the six sialylated *N*-linked glycan monosaccharide compositions occupying the three *N*-glycosylation sites of bovine fetuin i.e. (A) Asn81, (B) Asn138 and (C) Asn158. The relative quantitation is based on MALDI TOF MS signal intensities of free non-reduced sialoglycans, 2-AA labelled sialoglycans and tryptic sialoglycopeptides were all recorded in negative ion linear mode. These profiles are compared to a reference profile of methylated (stabilised) fetuin sialoglycans (black outline, see key for explanation). The figure is modified with permission from Thaysen-Andersen *et al.* *Anal. Chem.*, 2009, **81**, 3933–3943,¹⁰² which also contains more information about the specific experiment.

technique in the low femtomolar range.⁸⁸ Another systematic study reported that D-arabinosazone was superior to other matrices in negative ion MALDI MS by yielding higher signal strength and lower salt adduct formation than more common matrices.⁹¹ In addition, spermine minimised the adduct formation of sialoglycans when used as a co-matrix with DHB.⁹² Furthermore, modified CHCA matrices have proved superior for the analysis of sialoglycans: chlorinated CHCA (Cl-CHCA) was shown to minimise desialylation of *N*- and *O*-linked sialoglycans by eliminating MS induced in-source and metastable decay in negative ion MALDI MS⁹³ and the 1,1,3,3-tetramethylguanidium (TMG) salt of CHCA generated preferential ionisation of sialoglycans.⁹⁴

2.2.1.c Instrument settings in MALDI MS. In addition to the in-source (or ‘prompt’) fragmentation, the sialoglycans can also be desialylated post source in the ion transfer or downstream in the mass analyzer, a mechanism termed post-source decay. For example, desialylation occurring post source is normally very visible for MALDI time-of-flight (TOF) MS performed in reflectron mode with the extraction delay functionality enabled.^{12,40} This can largely be avoided by performing the acquisition in linear mode with limited, or even without, extraction delay of the generated ions, but at a significant expense of signal

resolution.⁹⁵ Another example is the pulsed application of cooling gas in MALDI fourier transform-ion cyclotron resonance (FT-ICR) MS, which together with a low extraction voltage, promises to minimise the loss of sialic acid residues from sialoglycans.⁴⁰ In comparison, significant losses of sialic acid residues occur in a typical vacuum MALDI source without cooling of the sialoglycan ions.⁷⁹ Hence, abundant losses of sialic acids seem avoidable by using intermediate pressure MALDI sources where the sialoglycans are allowed to dissipate excess energy prior to the mass analysis. This, in turn, opens up the use of ‘hotter’ and more user-friendly matrices facilitating easier sample preparation and data acquisition for MALDI MS based analysis of sialoglycoconjugates.^{96–98}

2.2.1.d Quantitation. Until recently, quantitative profiling of sialylated and neutral glycans was mostly performed using normal phase chromatography (NPC) based separation and fluorescence detection of glycans labelled at the reducing end *e.g.* with PA, 2-AB or 2-AA;^{99,100} but this approach lacks speed and the capacity to resolve some structural configurations such as some fucosylated structures from their non-fucosylated counterpart. Recent advances in NPC, however, have increased its peak capacity and the speed of acquisition.⁵¹ Due to the higher speed and sensitivity, MALDI MS based quantitation has been

investigated as an alternative to NPC for quantifying sialoglycans. It was found that MALDI MS signal intensities can be used as accurate and reproducible quantitative measures of the relative *N*-glycan distribution when populations consisting only of sialylated or neutral glycans are analysed separately in their native or derivatised forms, Fig. 2.^{88,101–104} In contrast, when mixtures of sialylated and non-sialylated glycans are analysed together, significant detection biases for or against sialoglycans are observed depending on the MS polarity mode.^{2,11,102,103,105,106} This limits the use of MALDI MS for direct accurate quantitation of biological mixtures, which usually comprise sialo and asialo *N*- and *O*-linked glycans. To obtain equal ionisation responses for sialylated and neutral glycans it has been suggested to either neutralise the charge on the carboxyl group of the sialic acid residues by derivatisation or to modify the MALDI matrix. For the charge neutralisation, the quantitative detection biases were overcome by simple methyl esterification^{107–109} or amidation¹⁰⁶ (see *Part I* of the review³ for more information). This permanent charge neutralisation yielded very accurate relative quantitation of sialylated and neutral reducing-end labelled *N*-glycans when analysed in positive ion MALDI TOF MS in good agreement with quantitation profiles obtained by conventional NPC separation and fluorescence detection.^{109,110} For the matrix modification, spiking the matrix with trace amounts of either H_2SO_4 or alkylsulfonates yielded equal in-spectrum ionisation responses in negative ion MALDI MS of neutral glycans (observed as $[\text{M} + \text{H}_2\text{SO}_4]^-$ or $[\text{M} + \text{RSO}_3]^-$ ions) and sialoglycans (observed as $[\text{M} - \text{H}]^-$ ions).^{111,112} Another group introduced a light and heavy tag in the reaction step for the reducing end labelling with 2-AA to yield accurate glycoform quantitation of the glycans between different samples (but not necessarily between the glycans within a given sample) using negative ion MALDI TOF MS.¹¹³

2.2.2 ESI MS

2.2.2. *a* *Ionisation.* Non-reduced or reduced native sialoglycans are commonly analysed in negative ion ESI MS because of the higher signal response in this ion polarity in which MALDI MS shows lower performance. On the other hand, permethylated sialoglycans produce stronger signal responses in positive ion ESI MS compared to their underderivatised equivalents.¹¹⁴ Compared to MALDI, ESI inherently generates cooler ions and limited ionisation induced fragmentation is consequently observed when gentle desolvation settings of the source are used.^{17,77} Here deprotonation is the dominating ion formation rather than ionisation by anion adduction. Unlike sialoglycans, neutral glycans usually appear in negative ion ESI MS as the anion adducts when doped with anions such as chloride.¹¹⁵ However, neutral glycans can also be ionised in negative ion mode as $[\text{M} - \text{H}]^-$ ions without anion doping. As described below, another advantage of negative ion ESI MS is that sialylated and neutral native glycans ionise with more similar ionisation efficiencies, which is beneficial for quantitation purposes. In addition, negative ion MS usually gives more informative CID fragmentation spectra when native reduced glycans are analysed by tandem MS. This has paved the way for detailed characterisation of many sialylated glycans derived from both *N*- and *O*-linked sialoglycoproteins.^{116–119} Structural information obtained includes monosaccharide compositions,

topologies, branches and linkage types; however, extraction of parts of such structural information is often dependent on the simultaneous use of PGC retention time information and parallel exoglycosidase treatment.¹²⁰

2.2.2. *b* *Quantitation.* The same ionisation biases of neutral and sialylated glycans observed in MALDI may apply for ESI, but such ionisation differences, if any, have been reported to be less prominent in ESI MS.^{11,34,40,121} Some researchers have actually observed no significant ionisation differences between native sialo- and asialoglycans when analysed in negative ion ESI MS when evaluated quantitatively against the glycan profile obtained using conventional NPC analysis of the same sample.¹²² In support, signal intensities were found to be an accurate measure of the quantitative amounts of sialylated and neutral reduced *N*-glycans from human prostate specific antigen when recorded in negative ion ESI MS on an ion trap (IT) MS.¹²³ However, in ESI MS, the sialoglycans are observed with different ion charge state distributions than neutral glycans meaning that all observed charge states need to be considered to obtain accurate quantitation.¹¹ In a systematic study using PGC ESI MS it was concluded that solvent pH has marginal effect on the ionisation efficiency of sialoglycans in positive and negative ion ESI MS, but that the content of the organic solvent strongly influences the signal strength.³⁴ The same researchers concluded that positive ion ESI MS appears preferable when neutral and sialylated glycans are quantified in the same sample. Others have calculated the difference in signal response factors of some sialylated and non-sialylated glycans released from mucins in negative ion ESI MS such that the biased detection of sialoglycans is able to be compensated for.¹²⁴ The permanent charge neutralisation techniques used for derivatisation of sialoglycans, including methyl esterification, amidation and permethylation as described previously,³ are also compatible with downstream ESI MS based analysis. As an example, permethylation enabled accurate quantitation of mixtures of neutral and sialylated *N*-glycans derived from specific glycoproteins by MS driven glycoprofiling based on comparison with profiles obtained using NPC analysis of 2-AB labelled *N*-glycans derived from the same glycoproteins.¹²⁵ Detection biases for or against sialoglycan ion intensities in ESI and MALDI MS becomes less important when comparative studies are undertaken since any suppression or underrepresentation of each glycan species would occur in both samples. The literature harbours plenty of examples of such comparative studies where the accuracy of the individual relative amounts of each component within a sample is of lower importance than the relative differences between samples. As an example, this was illustrated in a study where the cytokines interleukin-1 β and tumor necrosis factor- α were shown to quantitatively induce a shift towards expression of glycoproteins carrying α 2,3-linked sialic acid containing glycans in primary human chondrocytes compared to the expression of this linkage type before cytokine treatment.¹²⁶ Direct quantitative comparison of released sialoglycans from two sample origins may also be quantified using a recently introduced glyco tandem mass tag, which showed accurate quantification over a broad dynamic range.¹²⁷



2.2.3 Fragmentation. The general fragmentation of native, reducing-end labelled and permethylated glycans has been covered previously.^{77,114,128} The fragmentation of sialylated glycans using either ESI or MALDI MS will be briefly discussed in the following. The multiply charged protonated or deprotonated ions produced in ESI MS, as compared to the singly charged and partly adducted ions typically formed in MALDI MS, produce different fragmentation pathways in the different charge states.¹²⁹ Deprotonated sialoglycan ions in negative ion MS appears to be more stable in the gas-phase than their neutral counterparts meaning that more energy is required to fragment such species to the same extent.¹³⁰ Monosaccharide rearrangements during the fragmentation event have been systematically described and it appears that mostly protonated glycans and glycoconjugates in positive ion mode as opposed to deprotonated and adducted ions are affected during the ionisation process.¹³¹ Thus, caution has to be taken when interpreting tandem MS spectra obtained from protonated glycoconjugate ions. However, rearrangements have predominantly been associated with deoxyhexose residues (*i.e.* fucose residues) and not sialic acid residues on *N*- and *O*-linked glycans.^{129,132,133}

2.2.3.a CID for tandem MS and multistage MSⁿ. Collision induced dissociation (CID) is by far the most used fragmentation technique for biomolecules in modern MS. CID is also routinely used to fragment sialylated and neutral *N*- and *O*-linked glycans. The general monosaccharide compositions of sialoglycans may be elucidated and confirmed by the presence of abundant B/C- and Y/Z-type ions generated from glycosidic bond cleavages using lower energy CID tandem MS fragmentation which is feasible on various mass spectrometers including triple quadrupoles (Q), IT, Q-TOF and FT-ICR analyzers. Native sialylated glycans tend to produce an abundant B₁-ion (*e.g.* *m/z* 290 for Neu5Ac and *m/z* 306 for Neu5Gc containing glycans, respectively in negative ion MS) reducing the abundance of the informative C-type ions.¹¹⁴ Higher energy CID fragmentation, which can be obtained on MALDI TOF-TOF instrumentation yields more cross-ring cleavages such as X-type ions of neutral and sialylated glycans.¹³⁴ Fragmentation of sialylated and neutral *N*-glycans labelled with 2-AA generates mostly Y-type ions and some A-type cross-ring cleavages.¹³⁵ Again it is stressed that the fragmentation pattern and, hence, the structural information obtained by tandem MS varies depending on the charge state and the polarity of the molecular precursor.

Cross-ring cleavages in the forms of A_n- and X_n-ions are often needed to interpret the fine structure of native sialoglycans. In contrast, some linkage and topology information can be extracted from so-called 'scars' generated from glycosidic cleavages of permethylated sialoglycans.⁷⁶ Such information is based on the appearance of unmodified hydroxyl groups formed during tandem MS of the permethylated sialoglycans indicating which glycosidic bonds have been broken and which hydroxyl groups were originally free. The arm-specific position of sialic acid residues on native multi-antennary *N*-glycans has been obtained using negative ion ESI tandem MS on Q-TOF mass




Fig. 3 Complementary fragmentation of 2-AA- (A and B) and 2-AB- (C and D) labelled *N*-linked sialoglycans derived from human transferrin using IRMPD (A and C) and EDD MS/MS (B and D). The resulting fragment ions are indicated on the structures. Figure adapted with permission.¹⁵¹

analyzers.¹³⁶ For this type of analysis the D-ion, which is defined as the fragment ion formed by the loss of the 3' antenna together with the *N*-glycan chitobiose core, is very informative.¹⁴ In addition, it has been shown that the two common sialic acid linkages (α 2,3- or α 2,6-) can be differentiated in positive ion ESI MS using CID fragmentation in combination with transition metal-ligand derivatisation.¹³⁷ For permethylated sialoglycans, the formation of specific A-type ions in positive ion ESI MS was shown to allow differentiation of α 2,3- or α 2,6-sialyl linkage isomers.¹³⁸⁻¹⁴⁰ Cross-ring cleavages that provided valuable linkage information of the structure of permethylated sialoglycans were also observed in positive ion MALDI TOF-TOF MS using higher energy CID fragmentation.¹⁴¹

Negative ion multistage MSⁿ where the molecular precursor is undergoing several rounds of isolation, fragmentation and mass separation/analysis has been shown to be capable of distinguishing closely related PA-labelled *N*-linked sialoglycans using a linear IT-TOF mass analyzer.^{142,143} The resulting fragment mass spectra was sufficiently reproducible and unique to enable differentiation of the topological isomers (*e.g.* specific fragments could be used to distinguish between *N*-glycans with sialic acid residues on either 3' or 6' arm) as well as the sialyl linkage type isomers (*e.g.* distinguish between structures carrying α 2,3- or α 2,6-Neu5Ac) by spectral matching. In addition, the C₄- and D-type ions in MS³ enhanced the confidence in the assignment. The identification of glycans by MSⁿ spectral matching had been suggested previously.¹⁴⁴ The need to perform multistage MSⁿ to structurally analyse sialoglycans by first removing the sialic acid(s) in the first round of fragmentation was stressed in a recent publication.³³ Here the on-line MSⁿ analysis was enabled using nano-flow PGC MS with alkaline mobile phases in negative ion mode for the sensitive detection of the sialoglycans. In addition, sialic acid linkage determination on *O*-linked sialoglycans using negative ion ESI MSⁿ on IT instrumentation was recently reported.¹⁴⁵ Furthermore, polarity switching combined with MSⁿ was found to be beneficial for characterising 2-AB labelled sialylated and neutral *N*-glycans separated by RPC.¹⁴⁶ Multistage MSⁿ was also used to fragment and characterise charge neutralised free oligosialic acids using negative ion ESI MS.⁹ In the same study, MALDI MSⁿ



proved capable of characterising the larger polysialic acids. Here, laser induced dissociation produced a range of different fragments including novel cross-ring cleavages (e.g. ${}^{3,5}\text{L}$ fragment ions), more classical ring fragments (e.g. ${}^{0,2}\text{A}$ - and ${}^{0,4}\text{A}$ -type ions) and common fragment ions generated by glycosidic bond cleavages.⁹ Different pyrene labels including pyrene butanoic acid hydrazide and 1-pyrenyl diazomethane (PDAM) derivatives have proved useful for the characterisation of sialoglycans in negative ion MALDI MSⁿ by yielding A-, D- and Y-ions.^{147,148} Taken together, multistage MSⁿ is a powerful approach for deep characterisation of sialoglycans; however, considering the much increased time and sample consumption of each additional tandem MS stage, multistage MSⁿ is probably most useful for abundant sialoglycan structures. Hence, for global glycome profiling purposes it is generally desirable to obtain the structural information in a single stage of tandem MS.⁷⁷

2.2.3.b Other fragmentation techniques. Fragmentation techniques other than CID have increasingly been used for native and derivatised sialoglycans. Similar to CID, infrared multiphoton dissociation (IRMPD) facilitates dissociation by collisional heating and, hence, mostly generates cleavages of the most labile bonds, the glycosidic bonds.⁷⁷

Activated electron dissociation (ExD) has recently received some attention in glycomics because cross ring cleavages of the monosaccharides of the glycans are being generated upon activation using ExD. This produces fragment ions which complement the fragments obtained by glycosidic cleavages. However, only limited work has been presented for sialoglycans. In recent studies, electron capture dissociation (ECD)¹⁴⁹ and electron transfer dissociation (ETD)⁷⁷ both produced glycan fragment ions that complemented the ions obtained from CID type fragmentation events. In addition, electron detachment dissociation (EDD) of sialoglycans was shown to be efficient for sialoglycan characterisation by yielding complementary structural information to that obtained from IRMPD by the formation of additional A-type cross-ring cleavages, Fig. 3.^{150,151} Even better performance of EDD fragmentation of sialoglycans was obtained with chloride anion attachment.¹⁵²

Higher-energy C-trap dissociation (HCD) and pulsed-Q-dissociation (PQD) are alternative fragmentation techniques to CID on the LTQ-Orbitrap platform.^{153,154} The complementarity of HCD and PQD to CID was shown for neutral linear and cyclic glycans,¹⁵⁵ but the performance of these fragmentation techniques still needs to be established for sialoglycans.

Post-source decay fragmentation in MALDI TOF MS was also shown to be capable of differentiating α 2,3- and α 2,6-linked sialic acids on sialyllactose and sialyl-*N*-acetyllactosamines.¹⁵⁶ Finally, laser-induced photofragmentation, which was shown to produce diagnostic ions for specifying the sialyl linkages of *N*-linked sialoglycans represents another exciting fragmentation technique for native and modified sialoglycans.¹⁵⁷

3. LC-MS analysis of sialoglycopeptides

Sialylated glycopeptides, which is usually generated by hydrolysis of sialoglycoproteins by specific or unspecific proteases (see more in *Part I* of the reviews paragraph 3.2.1³), can vary

dramatically in size and charge. Where *N*-linked sialoglycopeptides typically have a single, but larger, *N*-linked sialoglycan per proteolytically generated peptide, mucin type *O*-linked sialoglycopeptides may contain multiple shorter *O*-sialoglycans in clusters inaccessible to proteases. To date, a universal workflow capable of analysing the full range of sialylated glycopeptides that can be encountered in nature remains undescribed. Custom made experimental designs tailored to the specific research question being investigated are consequently still required in glycoproteomics to yield information-rich data. This means that relative few glycoproteins has been site-specifically glycoprofiled (list of profiled mammalian *N*-glycoproteins can be found in supplementary data in a recent publication¹⁵⁸). In contrast to released sialoglycans, the negative charge provided by the sialic acid on the sialoglycopeptides is not a unique feature since it is buffered by negative and positive charges from the acidic and basic amino acid residues of the attached polypeptide chain. Nonetheless, as described in the first of these two reviews,³ efficient enrichment tools are available to isolate the sialoglycopeptides from the neutral subset of the glycoproteome (or glycopeptidome) as well as from the non-glycosylated component for the enhanced analysis of sialoglycopeptides using LC-MS techniques.

3.1 LC separation of sialoglycopeptides

3.1.1 RPC. Due to the high peak capacity and the compatibility with conventional proteomics-based LC-MS platforms present in many analytical laboratories, RPC is by far the most popular technique for off- and on-line LC separation of glycopeptides.² Although the peptides arising from proteolytic digestion usually are very well resolved, there is limited separation of the micro-heterogeneous glycopeptides using RPC. Most neutral glycosylated variants of a given peptide will generally elute together in a single broad peak just before the non-glycosylated variant due to the higher hydrophilicity conferred by the attached glycan moieties.² This co-elution of the various neutral glycopeptide isoforms can be an advantage for identification and quantitation purposes, particularly for more complex peptide mixtures, by limiting the signal interference from other peptides. Sialylated glycopeptides tend to elute at a slightly higher acetonitrile concentration in RPC if no ion pairing (IP) reagents are present in the mobile phase (see Table 1 for overview of LC based separation of sialoglycopeptides). This indicates that sialic acid residues (*i.e.* Neu5Ac) contribute with a significant hydrophobicity to the sialoglycopeptide, possibly from the acetamido group at C5. In contrast, the opposite retention behavior is observed in the presence of IP reagents as shown by researchers using a modified mobile phase system consisting of 1 mM ammonium acetate, pH 6.8 in aqueous and acetonitrile containing solvents.^{159,160} Here, the elution pattern of the sialoglycopeptides was changed to an order of decreased retention for glycopeptides containing a higher number of sialic acid residues although the reason for this was not discussed. This IP containing mobile phase yielded a highly efficient separation of *N*- and *O*-linked sialoglycopeptides from human EPO. In addition to promoting a



more confident structural identification by enabling tandem MS of the individual eluting species, the LC separation of sialoglycopeptides is useful to detect any related ionisation induced fragmentation.

3.1.2 HILIC. Although under-represented in the literature, HILIC is an interesting separation technique for sialylated glycopeptides that shows large potential. For example, *N*-linked sialoglycopeptides derived from recombinant human EPO having different numbers of sialic acid residues and antennas were convincingly separated.^{161,162} Even *O*-linked sialoglycopeptides could be isolated from human EPO after removal of *N*-glycosylation from the peptides with PNGase F. In addition, the Neu5Ac and the Neu5Gc sialoglycopeptide isoforms could be separated as well as their acetylated sialic acid derivatives. Utilising trifluoroacetic acid (TFA) and other IP reagents in the mobile phase together with a ZIC HILIC stationary phase proved highly efficient for the isolation and separation of *N*-linked sialylated and neutral glycopeptides from non-glycosylated peptides in a mixture of tryptic peptides.^{163–165} The loss of acid-labile sialic acid residues in 0.1% TFA has been shown to be negligible in the time scale of an LC experiment thus making TFA a good choice for an IP reagent.¹³ In addition, the separation of α 2,3- or α 2,6-Neu5Ac sialoglycopeptide isomers was impressively shown in other studies using ZIC HILIC.^{48,166}

3.1.3 Other separation techniques. Other chromatographic separation techniques have been used to separate sialylated glycopeptides, but mostly in off-line setups. Early work proved that neutral and sialylated glycopeptides can be separated using PGC^{25,167} and HPAEC.¹⁶⁸ For the former, it has been shown that only relatively hydrophilic (or small) glycopeptides will elute from PGC once retained onto the column.¹⁶⁹ To the best of our knowledge, no recent studies using PGC or HPAEC to separate *N*- and *O*-linked sialoglycopeptides have been published. In another application, the non-retained fraction of strong cation exchange chromatography was shown to effectively isolate sialoglycopeptides from neutral glycopeptides, which were selectively retained on the solid phase.^{170,171} Similarly, separation of sialoglycopeptides from asialoglycopeptides was achieved using off-line CE with downstream MALDI MS detection.¹⁷² Finally, serial lectin affinity chromatography consisting of immobilised *Sambucus nigra* agglutinin (SNA) and concanavalin A has been used to separate sialoglycopeptides prior to MS detection of deglycosylated peptides.^{173,174} Here, complex tri- and tetra-antennary sialylated *N*-glycopeptides could be separated from bi-antennary *N*-linked sialoglycopeptides.

3.2 MS detection of sialoglycopeptides

3.2.1 MALDI MS

3.2.1.a Ionisation. Due to the lower stoichiometry and the general hydrophilicity, sialoglycopeptides tend to have lower ionisation strength in MALDI MS compared to nonglycosylated peptides. Sialylated glycopeptides have mostly been analysed in positive ion MALDI MS where the detection is more sensitive.^{175–178} However, negative ion MALDI MS was shown to be a viable alternative to positive ion mode because of less discrimination in ionisation between neutral and sialoglycopeptides and more

informative fragmentation of the sialoglycopeptides using tandem MS.¹⁷⁹ In another study, on-plate derivatisation of the carboxyl group of the C-terminus as well as the acidic amino acid side chains and the sialic acid residues of the sialoglycopeptides with PDAM increased the intensities of sialylated and neutral glycopeptides relative to the non-glycosylated peptides, increased the stability of the sialoglycopeptides, and allowed their characterisation using negative ion MALDI MSⁿ.¹⁸⁰ The same authors also showed that the linkage of α 2,3- and α 2,6-Neu5Ac containing glycopeptides derivatised with PDAM could be distinguished using negative ion MALDI MS.^{5,148}

3.2.1.b Matrix choice. As for sialoglycans, the commonly used DHB and CHCA matrices are unsuitable for sialoglycopeptides due to significant losses of sialic acids during fragmentation under typical MALDI acquisition settings (*i.e.* reflector mode with delayed extraction enabled). Instead, cooler matrices are typically favoured. Both Cl-CHCA⁹³ and THAP^{88,102} are suitable matrices for negative ion MALDI MS of under-derivatised sialoglycopeptides with no ionisation-induced fragmentation observed, even with acquisition in reflector mode with delayed extraction enabled. Derivatised and thereby stabilised sialoglycopeptides *e.g.* with PDAM, can be analysed without sialic acid loss, even using the 'hotter' matrices including the popular DHB matrix.¹⁴⁸

3.2.1.c Instrument settings. As is the case for sialoglycans, sialoglycopeptides can lose their sialic acids post source in the ion transfer or downstream in the mass analyzer. Post source desialylation is normally detectable for MALDI TOF MS performed in reflectron mode with extraction delay. This can largely be avoided by performing the acquisition in linear mode with limited or even without extraction delay, but results in lower signal resolution. Another example of minimising the loss of sialic acids from sialoglycopeptides is the pulsed application of cooling gas in MALDI FT-ICR MS together with a low extraction voltage.¹⁸¹ In comparison, it was shown that sialoglycopeptides formed in a typical vacuum MALDI source suffered from significant losses of sialic acid residues due to the lack of cooling of the sialoglycopeptide ions.

3.2.1.d Quantitation. Relative quantitation of sialoglycopeptides by MALDI MS signal intensities has been shown to be accurate when the sample preparation and MS settings are carefully considered.¹⁰² However, sialylated glycopeptide mass signals are weaker than the signals arising from their non-sialylated counterparts irrespective of ion polarity, limiting the use of signal intensities for relative quantitation when sialo- and asialoglycopeptides are analysed together.^{86,182} Recently, it was shown that positive ion MALDI FT-ICR MS discriminates less against sialoglycopeptide ionisation than positive ion MALDI TOF MS; when analysed together by MALDI FT-ICR MS the sialylated glycopeptides and the asialylated counterparts yielded essentially the same MS signal responses.¹⁸¹

3.2.2 ESI MS

3.2.2.a Ionisation. ESI MS of sialoglycopeptides has mostly been carried out in positive ion mode. Although sialic acid residues are negatively charged, the charge state of sialylated glycopeptides, containing one or more sialic acid residues, is surprisingly higher than the corresponding deglycosylated



peptides in positive ion mode (unpublished observations and Lendal *et al.*, in preparation). The extra proton(s) may tentatively be assigned to the nitrogen atoms of the sialic acid residues or the fact that sialoglycopeptides have a higher mass, but more investigation is needed to confirm this. In a study comparing ionisation efficiencies, HILIC separated sialoglycopeptides were analysed in positive and negative ion MSⁿ.¹⁶⁶ Here positive ion mode was preferred since information on the sialoglycan structure was obtained already at the MS² stage by sequential glycosidic bond fragmentations (Y_n-type ions).¹⁶⁶ Information on the peptide structure was obtained at the MS³ stage through formation of polypeptide backbone fragment ions including b_n-type ions. In other studies, data acquisition combining positive and negative ion polarities with different fragmentation techniques was found to be very useful for characterising *N*- and *O*-linked sialoglycopeptides.^{183,184}

3.2.2.b Quantitation. ESI MS based relative quantitation of sialoglycopeptides using MS signal intensities has been shown to be accurate by careful consideration and optimisation of the sample preparation and MS settings.¹⁰² It needs to be emphasised that the intensities of all charge states of each sialylated glycopeptide need to be included in the quantitation since the glycopeptides isomers ionises in slightly different charge state distributions.¹¹⁸ Positive ion ESI MS intensities were recently shown to discriminate somewhat against sialoglycopeptides when analysed together with the asialylated glycopeptide counterpart.¹⁸¹ Importantly, this study also highlighted that both the neutral and negatively charged sialylated *N*-glycopeptide ions are dramatically under-represented compared to the non-glycosylated and deglycosylated counterparts when equimolar amounts are analysed in positive ion ESI and MALDI MS. These important findings should be considered when glycosylation site occupancy is evaluated by MS signal strength.

3.2.3 Fragmentation. The general principles of MS fragmentation of glycopeptides have already been reviewed.^{114,185-189} Fragmentation aspects involving sialoglycopeptides will briefly be discussed below.

3.2.3.a CID for tandem MS and multistage MSⁿ. The most popular fragmentation technique for analysis of sialylated glycopeptides is by far CID with acquisition in positive ion polarity. CID fragmentation of sialoglycopeptides is dominated by cleavages of the glycosidic linkages of the peptide bound sialoglycans generating B- and Y-ions.¹⁹⁰⁻¹⁹⁴ In particular, the sialic acid linkage to the penultimate residue is cleaved with high efficiency leading to a strong B₁ ion at *m/z* 290 (negative ion mode) or *m/z* 292 (and *m/z* 274, B₁-H₂O) (positive ion mode) and the corresponding Y-ions.¹⁹⁵ Extracted ion chromatograms for these B₁ ions and some oxonium ions (e.g. *m/z* 366, HexHexNAc in positive ion mode) are helpful in localising sialoglycopeptide tandem MS CID spectra in the LC-MS data.¹⁶¹ CID fragmentation is usually sufficient to verify the monosaccharide composition of the sialoglycopeptides when combined with the accurate molecular mass of the precursor.¹⁹⁶ Dedicated software has been developed to aid the determination of glycopeptide composition from tandem MS data.¹⁹⁷ However, the identification of the peptide carrier and the site-specific attachment is usually difficult due to low-intensity peptide fragment ions in

CID,¹⁹⁸ but can be obtained either through MSⁿ CID approaches or by alternative fragmentation techniques including HCD¹⁹⁹ or ExD¹⁸⁹ as described below. For the former, positive and negative ion ESI linear IT-TOF MSⁿ has been employed for the analysis of sialylated *N*-linked glycopeptides with rich structural information on the attached sialoglycans being generated.^{184,200} This led to the suggestion that the structural assignment of sialylated *N*-glycans on glycopeptides can be determined by MSⁿ spectral matching.¹⁸⁴ As in the analysis of released glycans, rearrangement during the tandem MS process is known to happen particularly for glycopeptides that ionise by protonation, but reports have mostly described deoxyhexose rearrangements and not rearrangements of sialic acid residues.^{131,132}

3.2.3.b HCD, ExD and other fragmentation techniques. Realising the limitations of CID fragmentation in determining the complete sialoglycopeptide structure, glycoscientists have increasingly explored the possibilities for using alternative fragmentation techniques for the characterisation of sialoglycopeptides. Infrared multiphoton dissociation (IRMPD) facilitates dissociation by collisional heating and hence generates cleavage of the most labile bonds, the glycosidic bonds. IRMPD is consequently rather similar to CID in its fragmentation behaviour,²⁰¹ but with additional polypeptide backbone fragmentation being observed.²⁰²

Activated electron dissociation (ExD) methods have become popular in MS of peptides, but limited work has been presented for sialoglycopeptides. Electron capture dissociation (ECD) was shown to produce ions that complement the ions generated from CID type fragmentation events.^{183,203,204} Proof-of-concept studies have also been presented for the related fragmentation technique electron transfer dissociation (ETD). Here, multi-sialylated glycopeptides were seemingly less efficiently fragmented compared to ETD of neutral glycopeptides, but orthogonal information on the sialoglycopeptide structure could still be obtained when dedicated bioinformatic tools were used to interpret the obtained data.^{169,205,206} Nonetheless, most researchers carry out ETD or ECD on neutral or desialylated glycans.^{207,208} Neutral loss of the sialic acids and general charge reduction were observed when sialylated *N*- and *O*-linked glycopeptides were analysed using ETD MS^{195,209}. An approach has been presented where ETD and ECD were utilised together with CID fragmentation to characterise formerly sialylated *N*- and *O*-linked glycopeptides following enrichment based on sialic acid capture and release of the sialic acids by acid hydrolysis prior to MS detection; however, in this approach no information on the conjugated sialoglycan is obtained.²¹⁰⁻²¹² Finally, fragmentation techniques using negative ion polarity including electron detachment dissociation (EDD) and negative ETD (nETD) may very well be useful for the analysis of sialoglycopeptides, but these alternative fragmentation techniques need more investigation.¹⁸⁹

The performance of CID combined with either HCD or ETD as parallel fragmentation techniques has been compared in a study where the neutral *N*-glycoproteome of *Campylobacter jejuni* was investigated.²¹³ The combination CID/HCD enabled identification of the glycan structure and peptide backbone whereas CID/ETD enabled elucidation of the glycosylation site.



In another study, 88 previously uncharacterised neutral *N*-glycopeptides were identified from hen egg glycoprotein mixtures using HCD and accurate molecular mass, but no sialylated glycopeptides were reported.²¹⁴ Recently, HCD and ETD were utilised in combination to identify a high number of neutral and sialylated *N*-linked glycopeptides of the secretome of human endothelial cells.²¹⁵ In this study alternating HCD-ETD detected predominantly high-intensity, multiply charged *N*-glycopeptides. HCD-product-dependent ETD preferentially selected complex/hybrid *N*-glycopeptide precursors for fragmentation. The benefits of using HCD fragmentation for *N*-linked sialoglycopeptides includes the presence of distinct Y_1 ions (peptide + GlcNAc), which can be used for further MS³ based identification, abundant oxonium ions and B-type ions (e.g. *m/z* 292 from Neu5Ac and *m/z* 657 from sialyl LacNAc) and the high mass accuracy, resolution and extended *m/z* range offered by the Orbitrap.¹⁹⁹ The combined use of CID, HCD and ETD on an Orbitrap instrumentation to characterise intact glycopeptides originating from the partly sialylated rat *N*-glycoproteome enabled identification of a total of 863 *N*-linked glycopeptides from 161 rat brain glycoproteins (Parker *et al.*, 2013, submitted). This deep *N*-glycoproteome analysis was aided by a parallel characterisation of the released *N*-glycome and sophisticated bioinformatic tools to identify and verify the glycopeptides as intact molecules. Moreover, a total of 569 unique *N*-linked intact sialylated glycopeptides from 190 unique peptide sequences were identified from 98 proteins in human plasma (S. Lendal *et al.*, in preparation). The identification of intact sialylated glycopeptides was performed using high accuracy mass spectrometry combined with computational tools.

3.3 LC-MS of sialoglycoproteins

Limited data has been presented for the LC-MS based analysis of intact sialoglycoproteins. However, this field is maturing quickly, driven by the well recognised analytical benefits of detecting the intact biomolecules instead of the post analysis piecing together the structural information in bottom up approaches.

3.3.1 LC separation of sialoglycoproteins. RPC is usually insufficient to separate the individual glycoforms of sialoglycoproteins showing extensive microheterogeneity such as human EPO and bovine α 1-acid-glycoprotein.²¹⁶ The sialoglycoforms elute as broad unresolved peaks since the larger protein component, which is identical for the glycoforms, largely determines the retention on RPC. Nevertheless, sialoglycoproteins from normal and pancreatic cancer sera, depleted for the 12 most abundant proteins, were separated and compared using wheat germ agglutinin, SNA and *Maackia amurensis* lectin enrichment and subsequent off-line RPC separation and UV detection of the intact sialoglycoproteins. The downstream glycopeptide mapping identified approximately 130 sialylated glycoproteins and identified significant changes in the abundance of specific sialoglycoproteins and glycosylation site occupancies in the pancreatic cancer sera compared to the normal healthy sera.²¹⁷

For increased LC resolution of sialoglycoforms, physico-chemical parameters other than hydrophobicity have been used for separation. Anion exchange chromatography (AEC) is a rational choice to separate the negatively charged sialoglycoproteins, although the negative charges from acidic amino acid residues in the polypeptide backbone can dilute the charge difference between the sialoglycoforms to a certain extent. Nonetheless, AEC was able to differentiate human kallikrein-6 sialylated isoforms comprising different numbers of sialic acid residues.^{218,219}

In addition to LC based separations, CE has proven very powerful in separating intact sialoglycoproteins. Glycoproteins with different numbers of sialic acid residues can routinely be separated using CE with either UV or molecular mass detection by ESI MS.^{117,220-225} Examples include CE-MS based separation and detection of glycoforms of intact bovine α 1-acid-glycoprotein (AGP) and fetuin that differed in the number of sialic acid residues.⁷² Glycoform separation was also shown for recombinant human EPO and transferrin using CE-UV or CE-MS, but in neither of these cases could the branching and linkage isoforms of the attached sialoglycans be resolved.^{220,221} Another very useful alternative for separating differently sialylated glycoproteins is two dimensional (2D) gel electrophoresis where the isoelectric focusing (IEF) in the first dimension is capable of separating sialoglycoforms.^{36,226} The higher the number of sialic acids residues, the more the migration of the sialoglycoform to the acidic end of the pH region of the IEF strip. Using high resolution IEF strips, sialoglycoforms differing by a single sialic acid residue can usually be resolved. One of the inherent limitations of this approach, however, is that membrane sialoglycoproteins are under-represented due to their low solubility in the detergents used for the IEF dimension.¹⁶ Recently, a systematic study established rules for roughly predicting the pI of sialoglycoproteins separated by 2D gel electrophoresis based on their sialic acid content.²²⁷

3.3.2 MS detection of sialoglycoproteins. Very limited work has been presented for the MS based detection of intact sialoglycoproteins. The microheterogeneity of apolipoprotein C3, which is a small partly sialylated *O*-linked glycoprotein, was determined by a mass profile at the intact glycoprotein level using linear mode MALDI TOF MS with sinapinic acid as matrix.²²⁸ A similar experimental setup was used for detecting the sialoglycoforms of human interferon- β and soluble CD59, two sialylated *N*-linked glycoproteins.^{176,229} However, a minor degree of MS induced desialylation was observed. Neutral glycoproteins appear with higher signal resolution in MALDI TOF MS using a THAP matrix instead of the sinapinic acid matrix which is commonly used for MALDI MS of intact non-glycosylated proteins.²¹⁶ Intact sialoglycoproteins were also observed with better signal resolution using 4-hydroxy-3-methoxybenzoic acid (also called ferulic acid) as a matrix in linear mode positive ion MALDI TOF MS. Lately, DHB and ATT were suggested to be suitable for MALDI TOF MS of sialylated glycoproteins, but the sialoforms of the glycoprotein remained partly unresolved.^{230,231} For this reason, most mass analyses of larger sialoglycoproteins showing extensive micro-heterogeneity has been performed with prior desialylation, yielding more resolved glycoforms.²³² MALDI based in-source decay has



been used to perform top-down sequencing of sialylated and non-sialylated *O*-linked glycoproteins of the mucin type.²³³ This revealed cell specific glycosylation site patterns (macroheterogeneity) and site-specific microheterogeneity of recombinant human MUC1 produced in HEK-293 and *Drosophila* S2 cells. The low efficiency of desolvation of intact sialylated and neutral glycoproteins has limited the use of ESI MS.¹⁶ However, this obstacle can be reduced by using nanospray ESI MS, which has resulted in the successful analysis of several sialylated and neutral glycoproteins.²³⁴ The use of very low nozzle/skimmer voltages, and smooth desolvation conditions were stressed as being crucial to detect the sialoglycoforms of bovine AGP.²³⁵ In other studies, a high number of sialylated glycoforms were determined by using accurate molecular mass measurements obtained using ESI TOF MS of CE separated isoforms of human EPO with and without parallel glycan analysis.^{221,222} Another group reported detection of the highly heterogeneous and heavily sialylated human AGP using ultra-high resolution ESI FT-ICR MS.²³⁶

3.3.3 Other detection techniques for sialoglycoproteins.

Until MS based techniques become sufficiently mature for the analysis of intact sialoglycoproteins alternative techniques are available for the detection of sialylated glycoproteins. As discussed in the first of these two related reviews,³ sialic acid specific lectins are ideal for detection and visualisation of sialoglycoproteins from tissues and fluids by enzyme-linked immunosorbent assay (ELISA) and histochemistry approaches. For example, SNA-antibody lectin ELISA could detect differences in α 2,6-linked sialic acid content of intact human kallikrein-6 from ovarian cancer ascites and cerebrospinal fluid,^{218,219} and at the system-wide cellular level on cancerous and healthy liver cell proteins.²³⁷ *O*-acetylated sialic acid residues on glycoproteins can be detected with specific lectins *i.e.* crab lectin from *Lioacrinus depurator* showing broad specificity towards *O*-acetyl sialic acid²³⁸ and lectins from *Cancer antennarius* and *Paratelphusa jacquemontii* showing specificity towards 4-*O*- and 9-*O*-acetylated sialic acid residues.^{239,240} The general identification and analysis of *O*-acetylated sialoglycoproteins have been recently reviewed.²⁴¹ Antibody detection of sialylated glycoproteins is another interesting approach that is currently being investigated. As an example, a reliable antibody-based method for the highly specific and sensitive detection of non-human Neu5Gc containing glycoconjugates in tissues and in biotherapeutics was recently presented.²⁴² An alternative method to antibody-based detection of sialoglycoproteins is the *in vitro* selection method from combinatorial RNA libraries that has been used for generating RNA/DNA molecules with high affinity and specificity towards specific biomolecules.^{243,244} Such RNA based aptamers have been developed to detect Neu5Ac sialoglycoproteins with high affinities.²⁴⁵ The technology may show the potential of discriminating subtle structural differences in sialoglycoproteins, which can prove useful for both enrichment and detection purposes.

4. Conclusion

Analytical glycoscience including the analysis of *N*- and *O*-linked glycoprotein sialylation has benefitted immensely

from the advancement of LC-MS technologies in recent decades. Many of these advancements have been driven by technology improvements within the larger proteomics research field. Due to the unique analytical challenges encountered in structural glycobiology, many of these technological improvements have only become useful for researchers in glycoscience after tailored alterations of the workflows and tedious method optimisation. This is in particular true for the analysis of glycoprotein sialylation where the lability of the sialic acid residues together with their negative charge, linkage and modification heterogeneity, demands dedicated workflows. Methods for sophisticated analyte manipulation where the sialoglycoconjugates are rendered more "LC-MS friendly" by chemical derivatisation prior to the LC-MS analysis have also played a significant part in the successful analytical achievements in recent years.

Although it still is commonly accepted that no analytical technique can yield the complete structural information regarding glycoprotein sialylation in a single analysis from a typical biological sample, LC-MS is gradually proving to be an extremely powerful approach to define the structure of sialoglycans and sialoglycopeptides at biologically relevant levels and complexities. Here it is important to stress that the biological function of the sialic acid and the protein glycosylation as a whole often can be learned from less-than-complete structural information of the sialylated *N*- or *O*-linked glycoprotein. In many known (and unknown) cases, however, the glycobiological function can be regulated by changes at the fine structural level such that the detailed and exact structure of the sialoglycoproteins is required to understand the underlying biology.

Although this review has focused on the analysis of the ubiquitous terminal modification of sialylation on *N*- and *O*-linked glycoproteins, it should be noted that our understanding of system glycobiology cannot be expected to be achieved by concentrating only on the sialylated protein component of the glycome/glycoproteome. The neutral glycome/glycoproteome equally needs to be specified from the same sample to define the entire glycosylation phenotype and to link this phenotype to biological functions. The spatial and temporal relationship with sialylated lipids is also important to consider particularly when cellular or system-wide processes are investigated. However, at this stage, holistic efforts are rarely undertaken due to the lack of such broad analytical knowledge and technology in a single laboratory.

At present, the main limitation of the available analytical techniques for determining glycoprotein sialylation includes the lack of automation of most experimental workflows. This obstacle severely limits the detailed structural characterisation of glycoprotein sialylation on the system-wide (cellular/organism) scale. Integration of bioinformatic tools and glycan repositories to aid the data handling and interpretation are on-going initiatives that are expected to facilitate greater coverage of the sialylated glycoproteome within the next few years by improving the throughput of data analysis. Spectral matching to libraries of tandem MS CID spectra of well-characterised sialylated *N*- and *O*-linked glycans is being pursued and will reduce the dependence on manual data



interpretation, which, at present, is limited to relatively few expert research groups. The requirement for expertise is even more pronounced for the interpretation of fragment MS spectra of sialoglycopeptides. Since tandem mass spectral matching approaches are presently unrealistic because of the astronomical number of possible sialoglycopeptides that can be encountered in a proteolytical digest of a biological sample (number of glycosylated *N*- and *O*-linked peptides in the proteome \times number of *N*- and *O*-linked sialoglycans in the glycome), bioinformatic tools and workflows must aim to assist the identification by partial *de novo* characterisation. This, in turn, relies strongly on the availability of well-understood fragmentation techniques including CID, HCD and ExD to allow acquisition of complementary structural information on the glycan structure, the peptide carrier as well as information on the sites of attachment.

LC-MS has proven capable of yielding accurate quantitative evaluation of sialylated and neutral glycans/glycopeptides comparable to the accuracy obtained using conventional UV-HPLC based detection techniques. However, accurate quantitation is highly dependent on the use of appropriate experimental designs since significant biases towards the derivatisation/ionisation/detection of some structures over others can be easily introduced during sample preparation and analyte detection. Recent advancements in the synthesis of sialoglycopeptides and glycoproteins using Fmoc solid-phase peptide synthesis^{169,246,247} may provide standards that will facilitate better understanding of fragmentation pathways and accurate definition of ionisation and detection efficiencies to yield more confident characterisation and quantitation of glycoprotein sialylation at the site-specific glycopeptide level.¹⁸¹

Another milestone to reach is the development and the further maturation and implementation of top-down MS technologies for the routine analysis of intact sialoglycoproteins. At present, little analytical work on intact sialoglycoproteins has been published, but the field is maturing rapidly.²⁴⁸ In addition to increasing the throughput of analysis by reducing the need for the extensive sample handling and processing required for bottom-up approaches, top-down approaches would allow researchers to study the intra-molecular relationships between sialoglycans on multiple glycosylation sites and other post-translational modifications to the intact polypeptide backbone. This would facilitate a more accurate characterisation of the individual "glycoforms" (more recently termed the "proteoform") than present-day bottom-up approaches.²⁴⁹ In the meantime migratory separation techniques such as 2D gels remain a helpful tool to visualise and separate sialylation on the intact glycoprotein level, but, needless to mention, at low resolution.²²⁶

In conclusion, remarkable analytical advances in the LC-MS technologies have been accomplished in recent decades enabling increased depth, sensitivity and accuracy in the characterisation of glycoprotein sialylation in biologically relevant samples. However, there are still unmet needs in structural glycobiology. Improvements are consequently needed at all analyte levels from sample preparation through LC-MS

acquisition to data analysis and interpretation. The combined efforts will allow us to dig deeper into the barely explored sialylated glycoproteome to address the functional relevance of sialic acid residues attached to specific glycoproteins.

Abbreviations

2-AA	2-Aminobenzoic acid
2-AB	2-Aminobenzamide
2D	Two-dimensional
AEC	Anion exchange chromatography
AGP	α 1-Acid-glycoprotein
ANTS	8-Aminonaphthalene-1,3,6-trisulfonic acid
APTS	8-Aminopyrene-1,3,6-trisulfonic acid trisodium
ATT	6-Aza-2-thiothymine
CE	Capillary electrophoresis
CHCA	α -Cyano-4-hydroxycinnamic acid
CID	Collision induced dissociation
Cl-CHCA	Chlorinated CHCA
CMP	Cytidine 5-monophosphate
DHB	2,5-Dihydroxybenzoic acid
ECD	Electron capture dissociation
EDD	Electron detachment dissociation
ELISA	Enzyme-linked immunosorbent assay
EPO	Erythropoietin
ESI	Electrospray ionisation
ETD	Electron transfer dissociation
ExD	Activated electron dissociation
FT-ICR	Fourier transform-ion cyclotron resonance
HCD	Higher-energy C-trap dissociation
HILIC	Hydrophilic interaction liquid chromatography
HPAEC	High pH anion exchange chromatography
IMS	Ion mobility spectrometry
IP	Ion pairing
IRMPD	Infrared multiphoton dissociation
Kdo	3-Deoxy-manno-octuloseonic acid
IEF	Isoelectric focusing
IT	Ion trap
LC	Liquid chromatography
MALDI	Matrix assisted laser desorption ionisation
MS	Mass spectrometry
NCAM	Neural cell adhesion molecule
nETD	Negative ETD
Neu5Ac	<i>N</i> -Acetylneurameric acid
Neu5Gc	<i>N</i> -Glycolylneurameric acid
NPC	Normal phase chromatography
PA	2-Aminopyridine
PDAM	1-Pyrenyl diazomethane
PGC	Porous graphitized carbon
PQD	Pulsed-Q-dissociation
Q	Quadrupole
RPC	Reversed phase chromatography
SNA	<i>Sambucus nigra</i> agglutinin
TFA	Trifluoroacetic acid
THAP	2,4,6-Trihydroxyacetophenone
TOF	Time-of-flight
UPLC	Ultra-high performance liquid chromatography
ZIC	Zwitter-ionic



Acknowledgements

We thank Dr Daniel Kolarich for critical reading of the manuscript. M.T.-A. was funded by the Australian Research Council by a Super Science Fellowship. GP was supported by the Danish Medical Science Research Council (Grant no. 11-107551). MRL was supported by the Lundbeck foundation (Junior Group Leader Fellowship).

References

- 1 J. L. Benesch and B. T. Ruotolo, *Curr. Opin. Struct. Biol.*, 2011, **21**, 641–649.
- 2 M. Wuhrer, A. M. Deelder and C. H. Hokke, *J. Chromatogr., B: Anal. Technol. Biomed. Life Sci.*, 2005, **825**, 124–133.
- 3 M. Thaysen-Andersen, M. R. Larsen, N. H. Packer and G. Palmisano, *RSC Adv.*, 2013, DOI: 10.1039/C3RA42960A.
- 4 A. G. Marshall and C. L. Hendrickson, *Annu. Rev. Anal. Chem.*, 2008, **1**, 579–599.
- 5 J. P. Kamerling and G. J. Gerwig, *Methods Mol. Biol.*, 2006, **347**, 69–91.
- 6 S. P. Galuska, H. Geyer, B. Weinhold, M. Kontou, R. C. Rohrich, U. Bernard, R. Gerardy-Schahn, W. Reutter, A. Munster-Kuhnel and R. Geyer, *Anal. Chem.*, 2010, **82**, 4591–4598.
- 7 S. G. Penn, M. T. Cancilla and C. B. Lebrilla, *Int. J. Mass Spectrom.*, 2000, **195**, 259–269.
- 8 S. P. Galuska, R. Geyer, M. Muhlenhoff and H. Geyer, *Anal. Chem.*, 2007, **79**, 7161–7169.
- 9 S. P. Galuska, H. Geyer, C. Bleckmann, R. C. Rohrich, K. Maass, A. K. Bergfeld, M. Muhlenhoff and R. Geyer, *Anal. Chem.*, 2010, **82**, 2059–2066.
- 10 Y. Wada, A. Dell, S. M. Haslam, B. Tissot, K. Canis, P. Azadi, M. Backstrom, C. E. Costello, G. C. Hansson, Y. Hiki, M. Ishihara, H. Ito, K. Kakehi, N. Karlsson, C. E. Hayes, K. Kato, N. Kawasaki, K. H. Khoo, K. Kobayashi, D. Kolarich, A. Kondo, C. Lebrilla, M. Nakano, H. Narimatsu, J. Novak, M. V. Novotny, E. Ohno, N. H. Packer, E. Palaima, M. B. Renfrow, M. Tajiri, K. A. Thomsson, H. Yagi, S. Y. Yu and N. Taniguchi, *Mol. Cell. Proteomics*, 2010, **9**, 719–727.
- 11 Y. Wada, P. Azadi, C. E. Costello, A. Dell, R. A. Dwek, H. Geyer, R. Geyer, K. Kakehi, N. G. Karlsson, K. Kato, N. Kawasaki, K. H. Khoo, S. Kim, A. Kondo, E. Lattova, Y. Mechref, E. Miyoshi, K. Nakamura, H. Narimatsu, M. V. Novotny, N. H. Packer, H. Perreault, J. Peter-Katalinic, G. Pohlentz, V. N. Reinhold, P. M. Rudd, A. Suzuki and N. Taniguchi, *Glycobiology*, 2007, **17**, 411–422.
- 12 L. R. Ruhaak, G. Zauner, C. Huhn, C. Bruggink, A. M. Deelder and M. Wuhrer, *Anal. Bioanal. Chem.*, 2010, **397**, 3457–3481.
- 13 J. S. Rohrer, G. A. Cooper and R. R. Townsend, *Anal. Biochem.*, 1993, **212**, 7–16.
- 14 D. J. Harvey, *Mass Spectrom. Rev.*, 1999, **18**, 349–450.
- 15 K. Marino, J. Bones, J. J. Kattla and P. M. Rudd, *Nat. Chem. Biol.*, 2010, **6**, 713–723.
- 16 H. Geyer and R. Geyer, *Biochim. Biophys. Acta*, 2006, **1764**, 1853–1869.
- 17 M. Pabst and F. Altmann, *Proteomics*, 2011, **11**, 631–643.
- 18 M. Wuhrer, *Glycoconjugate J.*, 2013, **30**, 11–22.
- 19 N. V. Artemenko, A. G. McDonald, G. P. Davey and P. M. Rudd, *Methods Mol. Biol.*, 2012, **899**, 325–350.
- 20 T. Lutteke, *Beilstein J. Org. Chem.*, 2012, **8**, 915–929.
- 21 M. Frank and S. Schloissnig, *Cell. Mol. Life Sci.*, 2010, **67**, 2749–2772.
- 22 A. Helenius and M. Aeby, *Annu. Rev. Biochem.*, 2004, **73**, 1019–1049.
- 23 L. R. Ruhaak, A. M. Deelder and M. Wuhrer, *Anal. Bioanal. Chem.*, 2009, **394**, 163–174.
- 24 M. Davies, K. D. Smith, A. M. Harbin and E. F. Hounsell, *J. Chromatogr.*, 1992, **609**, 125–131.
- 25 J. Q. Fan, A. Kondo, I. Kato and Y. C. Lee, *Anal. Biochem.*, 1994, **219**, 224–229.
- 26 N. G. Karlsson, N. L. Wilson, H. J. Wirth, P. Dawes, H. Joshi and N. H. Packer, *Rapid Commun. Mass Spectrom.*, 2004, **18**, 2282–2292.
- 27 W. Ni, J. Bones and B. L. Karger, *Anal. Chem.*, 2013, **85**, 3127–3135.
- 28 J. H. Knox and P. Ross, *Adv. Chromatogr.*, 1997, **37**, 73–119.
- 29 L. Pereira, *J. Liq. Chromatogr. Relat. Technol.*, 2008, **31**, 1687–1731.
- 30 P. H. Jensen, N. G. Karlsson, D. Kolarich and N. H. Packer, *Nat. Protoc.*, 2012, **7**, 1299–1310.
- 31 A. V. Everest-Dass, D. Jin, M. Thaysen-Andersen, H. Nevalainen, D. Kolarich and N. H. Packer, *Glycobiology*, 2012, **22**, 1465–1479.
- 32 S. Itoh, N. Kawasaki, M. Ohta and T. Hayakawa, *J. Chromatogr., A*, 2002, **978**, 141–152.
- 33 K. A. Thomsson, M. Backstrom, J. M. Holmen Larsson, G. C. Hansson and H. Karlsson, *Anal. Chem.*, 2010, **82**, 1470–1477.
- 34 M. Pabst and F. Altmann, *Anal. Chem.*, 2008, **80**, 7534–7542.
- 35 M. Pabst, J. Grass, R. Fischl, R. Leonard, C. Jin, G. Hinterkorner, N. Borth and F. Altmann, *Anal. Chem.*, 2010, **82**, 9782–9788.
- 36 Y. Mechref and M. V. Novotny, *Chem. Rev.*, 2002, **102**, 321–369.
- 37 F. T. Chen and R. A. Evangelista, *Electrophoresis*, 1998, **19**, 2639–2644.
- 38 M. Pabst, J. S. Bondili, J. Stadlmann, L. Mach and F. Altmann, *Anal. Chem.*, 2007, **79**, 5051–5057.
- 39 S. Hua, H. N. Jeong, L. M. Dimpasoc, I. Kang, C. Han, J. S. Choi, C. B. Lebrilla and H. J. An, *Anal. Chem.*, 2013, **85**, 4636–4643.
- 40 M. Wuhrer, A. R. de Boer and A. M. Deelder, *Mass Spectrom. Rev.*, 2009, **28**, 192–206.
- 41 G. Zauner, A. M. Deelder and M. Wuhrer, *Electrophoresis*, 2011, **32**, 3456–3466.
- 42 M. Thaysen-Andersen, K. Engholm-Keller and P. Roepstorff, in *Hydrophilic interaction liquid chromatography (HILIC) and advanced applications*, ed. P. G. Wang and W. He, CRC Press, Boca Raton, 2011, pp. 551–575.



43 Z. Hao, B. Xiao and N. Weng, *J. Sep. Sci.*, 2008, **31**, 1449–1464.

44 P. Hemstrom and K. Irgum, *J. Sep. Sci.*, 2006, **29**, 1784–1821.

45 A. J. Alpert, *Anal. Chem.*, 2008, **80**, 62–76.

46 Y. Takegawa, K. Deguchi, T. Keira, H. Ito, H. Nakagawa and S. Nishimura, *J. Chromatogr., A*, 2006, **1113**, 177–181.

47 Y. Yamakoshi, F. Yamakoshi, J. C. Hu and J. P. Simmer, *Eur. J. Oral Sci.*, 2011, **119**(suppl. 1), 234–240.

48 Y. Takegawa, K. Deguchi, H. Ito, T. Keira, H. Nakagawa and S. Nishimura, *J. Sep. Sci.*, 2006, **29**, 2533–2540.

49 K. Deguchi, T. Keira, K. Yamada, H. Ito, Y. Takegawa, H. Nakagawa and S. Nishimura, *J. Chromatogr., A*, 2008, **1189**, 169–174.

50 D. Kolarich, P. L. Turecek, A. Weber, A. Mitterer, M. Graninger, P. Matthiessen, G. A. Nicolaes, F. Altmann and H. P. Schwarz, *Transfusion*, 2006, **46**, 1959–1977.

51 J. Ahn, J. Bones, Y. Q. Yu, P. M. Rudd and M. Gilar, *J. Chromatogr., B: Anal. Technol. Biomed. Life Sci.*, 2010, **878**, 403–408.

52 M. Melmer, T. Stangler, A. Premstaller and W. Lindner, *J. Chromatogr., A*, 2011, **1218**, 118–123.

53 G. O. Staples, M. J. Bowman, C. E. Costello, A. M. Hitchcock, J. M. Lau, N. Leymarie, C. Miller, H. Naimy, X. Shi and J. Zaia, *Proteomics*, 2009, **9**, 686–695.

54 G. O. Staples, H. Naimy, H. Yin, K. Kileen, K. Kraiczek, C. E. Costello and J. Zaia, *Anal. Chem.*, 2010, **82**, 516–522.

55 Y. Takegawa, K. Deguchi, S. Ito, S. Yoshioka, H. Nakagawa and S. Nishimura, *Anal. Chem.*, 2005, **77**, 2097–2106.

56 J. Delaney and P. Vouros, *Rapid Commun. Mass Spectrom.*, 2001, **15**, 325–334.

57 X. Chen and G. C. Flynn, *Anal. Biochem.*, 2007, **370**, 147–161.

58 L. A. Gennaro, D. J. Harvey and P. Vouros, *Rapid Commun. Mass Spectrom.*, 2003, **17**, 1528–1534.

59 R. Zeleny, D. Kolarich, R. Strasser and F. Altmann, *Planta*, 2006, **224**, 222–227.

60 J. L. Behan and K. D. Smith, *Biomed. Chromatogr.*, 2011, **25**, 39–46.

61 D. C. Hurum and J. S. Rohrer, *J. Dairy Sci.*, 2012, **95**, 1152–1161.

62 R. R. Townsend, M. R. Hardy, D. A. Cumming, J. P. Carver and B. Bendiak, *Anal. Biochem.*, 1989, **182**, 1–8.

63 M. von Der Ohe, S. F. Wheeler, M. Wührer, D. J. Harvey, S. Liedtke, M. Muhlenhoff, R. Gerardy-Schahn, H. Geyer, R. A. Dwek, R. Geyer, D. R. Wing and M. Schachner, *Glycobiology*, 2002, **12**, 47–63.

64 J. R. Barr, K. R. Anumula, M. B. Vettese, P. B. Taylor and S. A. Carr, *Anal. Biochem.*, 1991, **192**, 181–192.

65 J. Bones, N. McLoughlin, M. Hilliard, K. Wynne, B. L. Karger and P. M. Rudd, *Anal. Chem.*, 2011, **83**, 4154–4162.

66 N. Takahashi, *J. Chromatogr., A*, 1996, **720**, 217–225.

67 W. Winkler, W. Huber, R. Vlasak and G. Allmaier, *Rapid Commun. Mass Spectrom.*, 2011, **25**, 3235–3244.

68 Y. Yamaguchi, W. Nishima, S. Re and Y. Sugita, *Rapid Commun. Mass Spectrom.*, 2012, **26**, 2877–2884.

69 M. M. Gaye, S. J. Valentine, Y. Hu, N. Mirjankar, Z. T. Hammoud, Y. Mechref, B. K. Levine and D. E. Clemmer, *J. Proteome Res.*, 2012, **11**, 6102–6110.

70 D. Isailovic, R. T. Kurulugama, M. D. Plasencia, S. T. Stokes, Z. Kyselova, R. Goldman, Y. Mechref, M. V. Novotny and D. E. Clemmer, *J. Proteome Res.*, 2008, **7**, 1109–1117.

71 Y. Mechref, *Electrophoresis*, 2011, **32**, 3467–3481.

72 E. Balaguer and C. Neususs, *Anal. Chem.*, 2006, **78**, 5384–5393.

73 L. A. Gennaro, J. Delaney, P. Vouros, D. J. Harvey and B. Domon, *Rapid Commun. Mass Spectrom.*, 2002, **16**, 192–200.

74 R. G. Jayo, J. Li and D. D. Chen, *Anal. Chem.*, 2012, **84**, 8756–8762.

75 O. Quintero, R. Montesino and J. A. Cremata, *Anal. Biochem.*, 1998, **256**, 23–32.

76 J. Zaia, *OMICS*, 2010, **14**, 401–418.

77 N. Leymarie and J. Zaia, *Anal. Chem.*, 2012, **84**, 3040–3048.

78 H. Nie, Y. Li and X. L. Sun, *J. Proteomics*, 2012, **75**, 3098–3112.

79 D. J. Harvey, *Mass Spectrom. Rev.*, 2006, **25**, 595–662.

80 D. J. Harvey, *Mass Spectrom. Rev.*, 2008, **27**, 125–201.

81 D. J. Harvey, *Mass Spectrom. Rev.*, 2009, **28**, 273–361.

82 D. J. Harvey, *Mass Spectrom. Rev.*, 2011, **30**, 1–100.

83 D. J. Harvey, *Mass Spectrom. Rev.*, 2012, **31**, 183–311.

84 P. Domann, D. I. Spencer and D. J. Harvey, *Rapid Commun. Mass Spectrom.*, 2012, **26**, 469–479.

85 J. Colangelo and R. Orlando, *Anal. Chem.*, 1999, **71**, 1479–1482.

86 C. W. Sutton, J. A. O'Neill and J. S. Cottrell, *Anal. Biochem.*, 1994, **218**, 34–46.

87 A. K. Powell and D. J. Harvey, *Rapid Commun. Mass Spectrom.*, 1996, **10**, 1027–1032.

88 D. I. Papac, A. Wong and A. J. Jones, *Anal. Chem.*, 1996, **68**, 3215–3223.

89 J. J. Pitt and J. J. Gorman, *Rapid Commun. Mass Spectrom.*, 1996, **10**, 1786–1788.

90 D. Sagi, P. Kienz, J. Denecke, T. Marquardt and J. Peter-Katalinic, *Proteomics*, 2005, **5**, 2689–2701.

91 S. F. Wheeler and D. J. Harvey, *Anal. Chem.*, 2000, **72**, 5027–5039.

92 Y. Mechref and M. V. Novotny, *J. Am. Soc. Mass Spectrom.*, 1998, **9**, 1293–1302.

93 M. H. Selman, M. Hoffmann, G. Zauner, L. A. McDonnell, C. I. Balog, E. Rapp, A. M. Deelder and M. Wührer, *Proteomics*, 2012, **12**, 1337–1348.

94 Y. Fukuyama, S. Nakaya, Y. Yamazaki and K. Tanaka, *Anal. Chem.*, 2008, **80**, 2171–2179.

95 L. R. Ruhaak, C. Huhn, W. J. Waterreus, A. R. de Boer, C. Neususs, C. H. Hokke, A. M. Deelder and M. Wührer, *Anal. Chem.*, 2008, **80**, 6119–6126.

96 M. H. Selman, L. A. McDonnell, M. Palmlad, L. R. Ruhaak, A. M. Deelder and M. Wührer, *Anal. Chem.*, 2010, **82**, 1073–1081.

97 E. Ito, A. Tominaga, H. Waki, K. Miseki, A. Tomioka, K. Nakajima, K. Kakehi, M. Suzuki, N. Taniguchi and A. Suzuki, *Neurochem. Res.*, 2012, **37**, 1315–1324.

98 P. B. O'Connor, E. Mirgorodskaya and C. E. Costello, *J. Am. Soc. Mass Spectrom.*, 2002, **13**, 402–407.



99 M. Nakano, K. Kakehi, M. H. Tsai and Y. C. Lee, *Glycobiology*, 2004, **14**, 431–441.

100 P. J. Domann, A. C. Pardos-Pardos, D. L. Fernandes, D. I. Spencer, C. M. Radcliffe, L. Royle, R. A. Dwek and P. M. Rudd, *Proteomics*, 2007, **7**(suppl. 1), 70–76.

101 D. J. Harvey, *Rapid Commun. Mass Spectrom.*, 1993, **7**, 614–619.

102 M. Thaysen-Andersen, S. Mysling and P. Hojrup, *Anal. Chem.*, 2009, **81**, 3933–3943.

103 G. C. Gil, Y. G. Kim and B. G. Kim, *Anal. Biochem.*, 2008, **379**, 45–59.

104 B. J. Harmon, X. Gu and D. I. Wang, *Anal. Chem.*, 1996, **68**, 1465–1473.

105 T. J. Naven and D. J. Harvey, *Rapid Commun. Mass Spectrom.*, 1996, **10**, 1361–1366.

106 M. Toyoda, H. Ito, Y. K. Matsuno, H. Narimatsu and A. Kameyama, *Anal. Chem.*, 2008, **80**, 5211–5218.

107 Y. Miura, Y. Shinohara, J. Furukawa, N. Nagahori and S. Nishimura, *Chemistry*, 2007, **13**, 4797–4804.

108 B. Kuster, A. P. Hunter, S. F. Wheeler, R. A. Dwek and D. J. Harvey, *Electrophoresis*, 1998, **19**, 1950–1959.

109 K. S. Jang, Y. G. Kim, G. C. Gil, S. H. Park and B. G. Kim, *Anal. Biochem.*, 2009, **386**, 228–236.

110 G. C. Gil, B. Iliff, R. Cerny, W. H. Velander and K. E. Van Cott, *Anal. Chem.*, 2010, **82**, 6613–6620.

111 A. W. Wong, M. T. Cancilla, L. R. Voss and C. B. Lebrilla, *Anal. Chem.*, 1999, **71**, 205–211.

112 A. W. Wong, H. Wang and C. B. Lebrilla, *Anal. Chem.*, 2000, **72**, 1419–1425.

113 S. Tep, M. Hincapie and W. S. Hancock, *Carbohydr. Res.*, 2012, **347**, 121–129.

114 J. Zaia, *Mass Spectrom. Rev.*, 2004, **23**, 161–227.

115 D. J. Harvey, *J. Am. Soc. Mass Spectrom.*, 2005, **16**, 622–630.

116 A. Lee, J. M. Chick, D. Kolarich, P. A. Haynes, G. R. Robertson, M. Tsoli, L. Jankova, S. J. Clarke, N. H. Packer and M. S. Baker, *Mol. Cell. Proteomics*, 2011, **10**, M900538MCP900200.

117 Z. Sumer-Bayraktar, T. Nguyen-Khuong, R. Jayo, D. D. Chen, S. Ali, N. H. Packer and M. Thaysen-Andersen, *Proteomics*, 2012, **12**, 3315–3327.

118 N. Deshpande, P. H. Jensen, N. H. Packer and D. Kolarich, *J. Proteome Res.*, 2010, **9**, 1063–1075.

119 Z. Sumer-Bayraktar, D. Kolarich, M. P. Campbell, S. Ali, N. H. Packer and M. Thaysen-Andersen, *Mol. Cell. Proteomics*, 2011, **10**, M111 009100.

120 D. Kolarich, A. Weber, P. L. Turecek, H. P. Schwarz and F. Altmann, *Proteomics*, 2006, **6**, 3369–3380.

121 S. Itoh, N. Kawasaki, N. Hashii, A. Harazono, Y. Matsuishi, T. Hayakawa and T. Kawanishi, *J. Chromatogr., A*, 2006, **1103**, 296–306.

122 J. Stadlmann, M. Pabst, D. Kolarich, R. Kunert and F. Altmann, *Proteomics*, 2008, **8**, 2858–2871.

123 N. Leymarie, P. J. Griffin, K. Jonscher, D. Kolarich, R. Orlando, M. McComb, J. Zaia, J. Aguilan, W. R. Alley, F. Altmann, L. E. Ball, L. Basumallick, C. R. Bazemore-Walker, H. Behnken, M. A. Blank, K. J. Brown, S. C. Bunz, C. W. Cairo, J. F. Cipollo, R. Daneshfar, H. Desaire, R. R. Drake, E. P. Go, R. Goldman, C. Gruber, A. Halim, Y. Hathout, P. J. Hensbergen, D. M. Horn, D. Hurum, W. Jabs, G. Larson, M. Ly, B. F. Mann, K. Marx, Y. Mechref, B. Meyer, U. Moginger, C. Neususs, J. Nilsson, M. V. Novotny, J. O. Nydalidhe, N. H. Packer, P. Pompach, B. Reiz, A. Resemann, J. S. Rohrer, A. Ruthenbeck, M. Sanda, J. M. Schulz, U. Schweiger-Hufnagel, C. Sihlbom, E. Song, G. O. Staples, D. Suckau, H. Tang, M. Thaysen-Andersen, R. I. Viner, Y. An, L. Valmu, Y. Wada, M. Watson, M. Windwarder, R. Whittal, M. Wuhrer, Y. Zhu and C. Zou, *Mol. Cell. Proteomics*, 2013, DOI: 10.1074/mcp.M113.030643.

124 F. J. Olson, M. Backstrom, H. Karlsson, J. Burchell and G. C. Hansson, *Glycobiology*, 2005, **15**, 177–191.

125 N. Viseux, X. Hronowski, J. Delaney and B. Domon, *Anal. Chem.*, 2001, **73**, 4755–4762.

126 M. Pabst, S. Q. Wu, J. Grass, A. Kolb, C. Chiari, H. Viernstein, F. M. Unger, F. Altmann and S. Toegel, *Carbohydr. Res.*, 2010, **345**, 1389–1393.

127 H. Hahne, P. Neubert, K. Kuhn, C. Etienne, R. Bomgarden, J. C. Rogers and B. Kuster, *Anal. Chem.*, 2012, **84**, 3716–3724.

128 M. Wuhrer and A. M. Deelder, *Rapid Commun. Mass Spectrom.*, 2006, **20**, 943–951.

129 D. J. Harvey, T. S. Mattu, M. R. Wormald, L. Royle, R. A. Dwek and P. M. Rudd, *Anal. Chem.*, 2002, **74**, 734–740.

130 J. L. Seymour, C. E. Costello and J. Zaia, *J. Am. Soc. Mass Spectrom.*, 2006, **17**, 844–854.

131 M. Wuhrer, A. M. Deelder and Y. E. van der Burgt, *Mass Spectrom. Rev.*, 2011, **30**, 664–680.

132 M. Wuhrer, C. A. Koeleman and A. M. Deelder, *Anal. Chem.*, 2009, **81**, 4422–4432.

133 M. Wuhrer, C. A. Koeleman, C. H. Hokke and A. M. Deelder, *Rapid Commun. Mass Spectrom.*, 2006, **20**, 1747–1754.

134 U. Lewandrowski, A. Resemann and A. Sickmann, *Anal. Chem.*, 2005, **77**, 3274–3283.

135 D. J. Harvey, *J. Mass Spectrom.*, 2005, **40**, 642–653.

136 D. Sagi, J. Peter-Katalinic, H. S. Conradt and M. Nimtz, *J. Am. Soc. Mass Spectrom.*, 2002, **13**, 1138–1148.

137 M. D. Leavell and J. A. Leary, *J. Am. Soc. Mass Spectrom.*, 2001, **12**, 528–536.

138 J. Lemoine, G. Strecker, Y. Leroy, B. Fournet and G. Ricart, *Carbohydr. Res.*, 1991, **221**, 209–217.

139 Y. Mechref and M. V. Novotny, *J. Chromatogr., B: Anal. Technol. Biomed. Life Sci.*, 2006, **841**, 65–78.

140 Y. Mechref, P. Kang and M. V. Novotny, *Rapid Commun. Mass Spectrom.*, 2006, **20**, 1381–1389.

141 W. Morelle, V. Faid and J. C. Michalski, *Rapid Commun. Mass Spectrom.*, 2004, **18**, 2451–2464.

142 K. Deguchi, Y. Takegawa, H. Ito, N. Miura, S. Yoshioka, S. Nagai, H. Nakagawa and S. Nishimura, *Rapid Commun. Mass Spectrom.*, 2006, **20**, 412–418.

143 H. Ito, K. Yamada, K. Deguchi, H. Nakagawa and S. Nishimura, *Rapid Commun. Mass Spectrom.*, 2007, **21**, 212–218.

144 A. Kameyama, N. Kikuchi, S. Nakaya, H. Ito, T. Sato, T. Shikanai, Y. Takahashi, K. Takahashi and H. Narimatsu, *Anal. Chem.*, 2005, **77**, 4719–4725.





145 E. Casal, R. Lebron-Aguilar, F. J. Moreno, N. Corzo and J. E. Quintanilla-Lopez, *Rapid Commun. Mass Spectrom.*, 2010, **24**, 885–893.

146 X. Chen and G. C. Flynn, *J. Am. Soc. Mass Spectrom.*, 2009, **20**, 1821–1833.

147 J. Amano, D. Sugahara, K. Osumi and K. Tanaka, *Glycobiology*, 2009, **19**, 592–600.

148 T. Nishikaze, T. Nakamura, H. Jinmei and J. Amano, *J. Chromatogr., B: Anal. Technol. Biomed. Life Sci.*, 2011, **879**, 1419–1428.

149 C. Zhao, B. Xie, S. Y. Chan, C. E. Costello and P. B. O'Connor, *J. Am. Soc. Mass Spectrom.*, 2008, **19**, 138–150.

150 J. T. Adamson and K. Hakansson, *J. Am. Soc. Mass Spectrom.*, 2007, **18**, 2162–2172.

151 W. Zhou and K. Hakansson, *Electrophoresis*, 2011, **32**, 3526–3535.

152 J. R. Kornacki, J. T. Adamson and K. Hakansson, *J. Am. Soc. Mass Spectrom.*, 2012, **23**, 2031–2042.

153 J. V. Olsen, B. Macek, O. Lange, A. Makarov, S. Horning and M. Mann, *Nat. Methods*, 2007, **4**, 709–712.

154 T. Guo, C. S. Gan, H. Zhang, Y. Zhu, O. L. Kon and S. K. Sze, *J. Proteome Res.*, 2008, **7**, 4831–4840.

155 C. Przybylski and V. Bonnet, *Rapid Commun. Mass Spectrom.*, 2013, **27**, 75–87.

156 T. Yamagaki and H. Nakanishi, *Glycoconjugate J.*, 1999, **16**, 385–389.

157 A. Devakumar, Y. Mechref, P. Kang, M. V. Novotny and J. P. Reilly, *Rapid Commun. Mass Spectrom.*, 2007, **21**, 1452–1460.

158 M. Thaysen-Andersen and N. H. Packer, *Glycobiology*, 2012, **22**, 1440–1452.

159 M. Ohta, N. Kawasaki, S. Itoh and T. Hayakawa, *Biologicals*, 2002, **30**, 235–244.

160 M. Ohta, N. Kawasaki, S. Hyuga, M. Hyuga and T. Hayakawa, *J. Chromatogr., A*, 2001, **910**, 1–11.

161 Y. Takegawa, H. Ito, T. Keira, K. Deguchi, H. Nakagawa and S. Nishimura, *J. Sep. Sci.*, 2008, **31**, 1585–1593.

162 J. Zhang and D. I. Wang, *J. Chromatogr., B: Biomed. Sci. Appl.*, 1998, **712**, 73–82.

163 W. Ding, H. Nothaft, C. M. Szymanski and J. Kelly, *Mol. Cell. Proteomics*, 2009, **8**, 2170–2185.

164 S. Mysling, G. Palmisano, P. Hojrup and M. Thaysen-Andersen, *Anal. Chem.*, 2010, **82**, 5598–5609.

165 W. Ding, J. J. Hill and J. Kelly, *Anal. Chem.*, 2007, **79**, 8891–8899.

166 O. Hernandez-Hernandez, R. Lebron-Aguilar, J. E. Quintanilla-Lopez, M. L. Sanz and F. J. Moreno, *Proteomics*, 2010, **10**, 3699–3711.

167 M. J. Davies, K. D. Smith, R. A. Carruthers, W. Chai, A. M. Lawson and E. F. Hounsell, *J. Chromatogr.*, 1993, **646**, 317–326.

168 J. S. Rohrer, *J. Chromatogr., A*, 1994, **667**, 75–83.

169 M. Thaysen-Andersen, B. L. Wilkinson, R. J. Payne and N. H. Packer, *Electrophoresis*, 2011, **32**, 3536–3545.

170 K. Lohrig, A. Sickmann and U. Lewandrowski, *Methods Mol. Biol.*, 2011, **753**, 299–308.

171 U. Lewandrowski, R. P. Zahedi, J. Moebius, U. Walter and A. Sickmann, *Mol. Cell. Proteomics*, 2007, **6**, 1933–1941.

172 S. I. Snovida, V. C. Chen, O. Krokhin and H. Perreault, *Anal. Chem.*, 2006, **78**, 6556–6563.

173 R. Qiu and F. E. Regnier, *Anal. Chem.*, 2005, **77**, 2802–2809.

174 R. Qiu and F. E. Regnier, *Anal. Chem.*, 2005, **77**, 7225–7231.

175 Z. Valnickova, M. Thaysen-Andersen, P. Hojrup, T. Christensen, K. W. Sanggaard, T. Kristensen and J. J. Enghild, *BMC Biochem.*, 2009, **10**, 13.

176 L. Dissing-Olesen, M. Thaysen-Andersen, M. Meldgaard, P. Hojrup and B. Finsen, *J. Pharmacol. Exp. Ther.*, 2008, **326**, 338–347.

177 M. Thaysen-Andersen, I. B. Thogersen, U. Lademann, H. Offenberg, A. M. Giessing, J. J. Enghild, H. J. Nielsen, N. Brunner and P. Hojrup, *Biochim. Biophys. Acta*, 2008, **1784**, 455–463.

178 M. Thaysen-Andersen, I. B. Thogersen, H. J. Nielsen, U. Lademann, N. Brunner, J. J. Enghild and P. Hojrup, *Mol. Cell. Proteomics*, 2007, **6**, 638–647.

179 C. C. Nwosu, J. S. Strum, H. J. An and C. B. Lebrilla, *Anal. Chem.*, 2010, **82**, 9654–9662.

180 J. Amano, T. Nishikaze, F. Tougasaki, H. Jinmei, I. Sugimoto, S. Sugawara, M. Fujita, K. Osumi and M. Mizuno, *Anal. Chem.*, 2010, **82**, 8738–8743.

181 K. Stavenhagen, H. Hinneburg, M. Thaysen-Andersen, L. Hartmann, D. Varon Silva, J. Fuchser, S. Kaspar, E. Rapp, P. H. Seeberger and D. Kolarich, *J. Mass Spectrom.*, 2013, **48**, 627–639.

182 Y. Zhang, E. P. Go and H. Desaire, *Anal. Chem.*, 2008, **80**, 3144–3158.

183 K. Deguchi, H. Ito, T. Baba, A. Hirabayashi, H. Nakagawa, M. Fumoto, H. Hinou and S. Nishimura, *Rapid Commun. Mass Spectrom.*, 2007, **21**, 691–698.

184 H. Ito, Y. Takegawa, K. Deguchi, S. Nagai, H. Nakagawa, Y. Shinohara and S. Nishimura, *Rapid Commun. Mass Spectrom.*, 2006, **20**, 3557–3565.

185 M. Wuhrer, M. I. Catalina, A. M. Deelder and C. H. Hokke, *J. Chromatogr., B: Anal. Technol. Biomed. Life Sci.*, 2007, **849**, 115–128.

186 U. M. Demelbauer, M. Zehl, A. Plematl, G. Allmaier and A. Rizzi, *Rapid Commun. Mass Spectrom.*, 2004, **18**, 1575–1582.

187 G. Zauner, R. P. Kozak, R. A. Gardner, D. L. Fernandes, A. M. Deelder and M. Wuhrer, *Biol. Chem.*, 2012, **393**, 687–708.

188 Y. Mechref, *Curr Protoc Protein Sci*, 2012, ch. 12, Unit 12.11 pp. 1–11.

189 E. D. Dodds, *Mass Spectrom. Rev.*, 2012, **31**, 666–682.

190 M. A. Ritchie, A. C. Gill, M. J. Deery and K. Lilley, *J. Am. Soc. Mass Spectrom.*, 2002, **13**, 1065–1077.

191 F. Wang, A. Nakouzi, R. H. Angeletti and A. Casadevall, *Anal. Biochem.*, 2003, **314**, 266–280.

192 Y. Satomi, Y. Shimonishi and T. Takao, *FEBS Lett.*, 2004, **576**, 51–56.

193 Y. Satomi, Y. Shimonishi, T. Hase and T. Takao, *Rapid Commun. Mass Spectrom.*, 2004, **18**, 2983–2988.

194 A. Kondo, M. Thaysen-Andersen, K. Hjerno and O. N. Jensen, *J. Sep. Sci.*, 2010, **33**, 891–902.

195 Z. Darula and K. F. Medzihradzky, *Mol. Cell. Proteomics*, 2009, **8**, 2515–2526.

196 J. W. Froehlich, M. Barboza, C. Chu, L. A. Lerno Jr, B. H. Clowers, A. M. Zivkovic, J. B. German and C. B. Lebrilla, *Anal. Chem.*, 2011, **83**, 5541–5547.

197 C. L. Woodin, D. Hua, M. Maxon, K. R. Rebecchi, E. P. Go and H. Desaire, *Anal. Chem.*, 2012, **84**, 4821–4829.

198 C. Zhang, A. Doherty-Kirby, R. Huystee Rv and G. Lajoie, *Phytochemistry*, 2004, **65**, 1575–1588.

199 Z. M. Segu and Y. Mechref, *Rapid Commun. Mass Spectrom.*, 2010, **24**, 1217–1225.

200 K. Deguchi, H. Ito, Y. Takegawa, N. Shinji, H. Nakagawa and S. Nishimura, *Rapid Commun. Mass Spectrom.*, 2006, **20**, 741–746.

201 K. Hakansson, M. J. Chalmers, J. P. Quinn, M. A. McFarland, C. L. Hendrickson and A. G. Marshall, *Anal. Chem.*, 2003, **75**, 3256–3262.

202 R. R. Seipert, E. D. Dodds, B. H. Clowers, S. M. Beecroft, J. B. German and C. B. Lebrilla, *Anal. Chem.*, 2008, **80**, 3684–3692.

203 F. Kjeldsen, K. F. Haselmann, B. A. Budnik, E. S. Sorensen and R. A. Zubarev, *Anal. Chem.*, 2003, **75**, 2355–2361.

204 K. F. Haselmann, B. A. Budnik, J. V. Olsen, M. L. Nielsen, C. A. Reis, H. Clausen, A. H. Johnsen and R. A. Zubarev, *Anal. Chem.*, 2001, **73**, 2998–3005.

205 D. Wang, M. Hincapie, T. Rejtar and B. L. Karger, *Anal. Chem.*, 2011, **83**, 2029–2037.

206 Z. Zhu, D. Hua, D. F. Clark, E. P. Go and H. Desaire, *Anal. Chem.*, 2013, **85**, 5023–5032.

207 K. Takahashi, S. B. Wall, H. Suzuki, A. D. T. Smith, S. Hall, K. Poulsen, M. Kilian, J. A. Mobley, B. A. Julian, J. Mestecky, J. Novak and M. B. Renfrow, *Mol. Cell. Proteomics*, 2010, **9**, 2545–2557.

208 M. Wuhrer, J. C. Stam, F. E. van de Geijn, C. A. Koeleman, C. T. Verrips, R. J. Dolhain, C. H. Hokke and A. M. Deelder, *Proteomics*, 2007, **7**, 4070–4081.

209 W. R. Alley Jr, Y. Mechref and M. V. Novotny, *Rapid Commun. Mass Spectrom.*, 2009, **23**, 161–170.

210 A. Halim, U. Ruetschi, G. Larson and J. Nilsson, *J. Proteome Res.*, 2013, **12**, 573–584.

211 J. Nilsson and G. Larson, *Methods Mol. Biol.*, 2013, **951**, 79–100.

212 A. Halim, J. Nilsson, U. Ruetschi, C. Hesse and G. Larson, *Mol. Cell. Proteomics*, 2012, **11**, M111 013649.

213 N. E. Scott, B. L. Parker, A. M. Connolly, J. Paulech, A. V. Edwards, B. Crossett, L. Falconer, D. Kolarich, S. P. Djordjevic, P. Hojrup, N. H. Packer, M. R. Larsen and S. J. Cordwell, *Mol. Cell. Proteomics*, 2011, **10**, M000031–MCP000201.

214 G. Hart-Smith and M. J. Raftery, *J. Am. Soc. Mass Spectrom.*, 2012, **23**, 124–140.

215 X. Yin, M. Bern, Q. Xing, J. Ho, R. Viner and M. Mayr, *Mol. Cell. Proteomics*, 2013, **12**, 956–978.

216 C. Sottani, M. Fiorentino and C. Minoia, *Rapid Commun. Mass Spectrom.*, 1997, **11**, 907–913.

217 J. Zhao, D. M. Simeone, D. Heidt, M. A. Anderson and D. M. Lubman, *J. Proteome Res.*, 2006, **5**, 1792–1802.

218 U. Kuzmanov, C. R. Smith, I. Batruch, A. Soosaipillai, A. Diamandis and E. P. Diamandis, *Proteomics*, 2012, **12**, 799–809.

219 U. Kuzmanov, N. Jiang, C. R. Smith, A. Soosaipillai and E. P. Diamandis, *Mol. Cell. Proteomics*, 2009, **8**, 791–798.

220 V. Sanz-Nebot, E. Balaguer, F. Benavente, C. Neususs and J. Barbosa, *Electrophoresis*, 2007, **28**, 1949–1957.

221 C. Neususs, U. Demelbauer and M. Pelzing, *Electrophoresis*, 2005, **26**, 1442–1450.

222 E. Balaguer, U. Demelbauer, M. Pelzing, V. Sanz-Nebot, J. Barbosa and C. Neususs, *Electrophoresis*, 2006, **27**, 2638–2650.

223 K. Kakehi, M. Kinoshita, D. Kawakami, J. Tanaka, K. Sei, K. Endo, Y. Oda, M. Iwaki and T. Masuko, *Anal. Chem.*, 2001, **73**, 2640–2647.

224 E. Watson and F. Yao, *Anal. Biochem.*, 1993, **210**, 389–393.

225 M. Kinoshita, E. Murakami, Y. Oda, T. Funakubo, D. Kawakami, K. Kakehi, N. Kawasaki, K. Morimoto and T. Hayakawa, *J. Chromatogr. A*, 2000, **866**, 261–271.

226 A. Rogowska-Wrzesinska, M.-C. Le Bihan, M. Thaysen-Andersen and P. Roepstorff, *J. Proteomics*, 2013, **88**, 4–13.

227 S. Barrabes, A. Sarrats, E. Fort, R. De Llorens, P. M. Rudd and R. Peracaula, *Electrophoresis*, 2010, **31**, 2903–2912.

228 Y. Zhang, A. R. Sinaiko and G. L. Nelsestuen, *Methods Mol. Biol.*, 2012, **909**, 141–150.

229 S. F. Wheeler, P. M. Rudd, S. J. Davis, R. A. Dwek and D. J. Harvey, *Glycobiology*, 2002, **12**, 261–271.

230 E. Gimenez, F. Benavente, J. Barbosa and V. Sanz-Nebot, *Rapid Commun. Mass Spectrom.*, 2007, **21**, 2555–2563.

231 E. Gimenez, F. Benavente, J. Barbosa and V. Sanz-Nebot, *Anal. Bioanal. Chem.*, 2010, **398**, 357–365.

232 G. Stubiger, M. Marchetti, M. Nagano, C. Reichel, G. Gmeiner and G. Allmaier, *Rapid Commun. Mass Spectrom.*, 2005, **19**, 728–742.

233 F. G. Hanisch, *Anal. Chem.*, 2011, **83**, 4829–4837.

234 M. Wilm and M. Mann, *Anal. Chem.*, 1996, **68**, 1–8.

235 M. Karas, U. Bahr and T. Dulcks, *Fresenius. J. Anal. Chem.*, 2000, **366**, 669–676.

236 K. Nagy, K. Vekey, T. Imre, K. Ludanyi, M. P. Barrow and P. J. Derrick, *Anal. Chem.*, 2004, **76**, 4998–5005.

237 D. Pousset, V. Piller, N. Bureaud, M. Monsigny and F. Piller, *Cancer Res.*, 1997, **57**, 4249–4256.

238 G. A. Fragkiadakis and E. K. Stratidakis, *Comp. Biochem. Physiol., Part B: Biochem. Mol. Biol.*, 1997, **117**, 545–552.

239 M. H. Ravindranath, D. L. Morton and R. F. Irie, *Cancer Res.*, 1989, **49**, 3891–3897.

240 M. Denis, P. D. Palatty, N. R. Bai and S. J. Suriya, *Eur. J. Biochem.*, 2003, **270**, 4348–4355.

241 C. Mandal, *Methods Mol. Biol.*, 2013, **981**, 57–93.

242 S. L. Diaz, V. Padler-Karavani, D. Ghaderi, N. Hurtado-Ziola, H. Yu, X. Chen, E. C. Brinkman-Van der Linden, A. Varki and N. M. Varki, *PLoS One*, 2009, **4**, e4241.

243 A. D. Ellington and J. W. Szostak, *Nature*, 1990, **346**, 818–822.

244 X. Ni, M. Castanares, A. Mukherjee and S. E. Lupold, *Curr. Med. Chem.*, 2011, **18**, 4206–4214.



245 S. Cho, B. R. Lee, B. K. Cho, J. H. Kim and B. G. Kim, *Biotechnol. Bioeng.*, 2013, **110**, 905–913.

246 N. Yamamoto, A. Takayanagi, T. Sakakibara, P. E. Dawson and Y. Kajihara, *Tetrahedron Lett.*, 2006, **47**, 1341–1346.

247 B. L. Wilkinson, R. S. Stone, C. J. Capicciotti, M. Thaysen-Andersen, J. M. Matthews, N. H. Packer, R. N. Ben and R. J. Payne, *Angew. Chem., Int. Ed. Engl.*, 2012, **51**, 3606–3610.

248 J. D. Tipton, J. C. Tran, A. D. Catherman, D. R. Ahlf, K. R. Durbin and N. L. Kelleher, *J. Biol. Chem.*, 2011, **286**, 25451–25458.

249 L. M. Smith, N. L. Kelleher, M. Linial, D. Goodlett, P. Langridge-Smith, Y. Ah Goo, G. Safford, L. Bonilla, G. Kruppa, R. Zubarev, J. Rontree, J. Chamot-Rooke, J. Garavelli, A. Heck, J. Loo, D. Penque, M. Hornshaw, C. Hendrickson, L. Pasa-Tolic, C. Borchers, D. Chan, N. Young, J. Agar, C. Masselon, M. Gross, F. McLafferty, Y. Tsybin, Y. Ge, I. Sanders, J. Langridge, J. Whitelegge and A. Marshall, *Nat. Methods*, 2013, **10**, 186–187.

250 E. D. Green, G. Adelt, J. U. Baenziger, S. Wilson and H. Van Halbeek, *J. Biol. Chem.*, 1988, **263**, 18253–18268.

251 M. Nakano, R. Saldanha, A. Gobel, M. Kavallaris and N. H. Packer, *Mol. Cell. Proteomics*, 2011, **10**, M111 009001.

